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ABSTRACT
According to the Centers for Disease Control, the geriatric population of ≥65
years of age will increase to 51.5 million in 2020; 40% of white women and 13% of
white men will be at risk for fragility fractures or fractures sustained under normal stress
and loading conditions due to bone disease, leading to hospitalization and surgical
treatment. Fracture management strategies can be divided into pharmaceutical therapy,
surgical intervention, and tissue regeneration for fracture prevention, fracture
stabilization, and fracture site regeneration, respectively. However, these strategies fail to
accommodate the pathological nature of fragility fractures leading to unwanted side
effects, implant failures, and non-unions.
Compromised innate bone healing reactions of patients with bone diseases is
exacerbated with protective bone therapy. Once these patients sustain a fracture, bone
healing is a challenge especially when fracture stabilization is unsuccessful. Traditional
stabilizing screw and plate systems were designed with emphasis on bone mechanics
rather than biology. Bone grafts are often used with fixation devices to provide skeletal
continuity at the fracture gap. Current bone grafts include autologous bone tissue and
donor bone tissue; however, there is insufficient quality and quantity demanded by
fragility fractures sustained by high-risk geriatric patients and patients with bone
diseases. Consequently, bone tissue engineering strategies are advancing towards
functionalized bone substitutes to resolve shortages in fracture reconstruction while
effectively mediating bone healing in normal and diseased fracture environments.
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In order to target fragility fractures, fracture management strategies should be
integrated for a synchronized treatment of prevention without hindrance to bone
regeneration and fracture stabilization with bioactive bone substitutes designed for the
pathological environment. However, the clinical outcome of these materials must be
predictable within various disease environments. Initial development of a targeted
treatment strategy should focus on simulating physiological in vitro bone environment to
predict clinical effectiveness of engineered bone while understanding cellular responses
due to the alternative agents and bioactive scaffolds. An in vitro testing system can be the
predicate to reducing implant failures and non-unions in fragility fractures.
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PREFACE
The number of bone grafting procedures performed annually was estimated, in
2001, to be 500,000 in the US and over 2.2 million worldwide, with an expected increase
of 13% per year exceeding the procurement of donor tissue [5-8]. The bone graft of
choice for surgeons is autologous bone tissue, harvested from the patient’s own bone,
commonly from the iliac crest. However, for patients with bone diseases, the natural
regenerative capability of bone is greatly hindered and further exaggerated with bone
protective drug therapies. The preferred alternative to an autograft is an allograft obtained
from donor tissue; however, limited donor supply has driven the development of
substitute bone biomaterials composed of polymers, ceramics, and their composites.
Bone tissue engineers have innovated and investigated a vast array of biomaterials
to mimic the mechanical, physiochemical, and biological properties of bone.
Additionally, chemical, molecular, and cellular mediators have been incorporated into
biomaterials to stimulate and enhance the bone healing cascade [11-14]. Early testing of
enhanced biomaterials are limited to in vitro characterizations of monocultures and cocultures that are inconsistent in design and mimicry to the natural bone environment.
With advance in understanding cellular and molecular biology of bone, a better in vitro
culture can be developed to be able to predict clinical outcome of the biomaterial for an
expedited journey to clinical applications.
An established standard in vitro multicellular culture system simulating aspects of
bone cell pathology will emphasize and overcome the pathological limitations of fracture
healing. A greater understanding of bone healing under pathological conditions have

allowed researchers to design cellular bone replacements that significantly reduce nonhealing fractures. Hence, a co-culture test system with relevant cell ratio to simulate
pathological conditions can account for specific environments or exaggerate the
anomalies. The proposed test system will utilized precursor osteoclasts and osteoblasts to
understand bone cell differentiation on commercially available bone substitute ChronOS
granules. The precursor cells are cultured at varying cell ratios of 1:1, 1:10, 1:100
(precursor osteoclast:osteoblast) to simulate pathological bone cell conditions in order to
predict clinical outcome of ChronOS as a treatment option for patients with abnormal
bone cell activity in bone formation and resorption of the material. The overall research
objective is to establish a standard co-culture condition using murine RAW monocytes
and D1 stromal cells at the specified cell ratios to elicit characteristic metabolic activity,
gene expression, and protein production native to bone formation. To translate research
concepts to the K-12 community, a teaching module was designed to introduce middle
and high school students to bone tissue engineering as a possible career aspiration within
biomedical engineering. To accomplish the overall objectives, four specific aims were
recognized as follows:
Aim 1: Determine co-culture cell ratio for RAW:D1 to differentiate into
osteoclast:osteoblast
Aim 2: Determine necessity for RANK ligand for osteoclastogenesis in presence of
osteoblasts
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Aim 3: Determine multicellular culture with co-culture of RAW:D1 for
osteoclast:osteoblast differentiation in presence of indirect culture with
adipocytes
Aim 4: Develop a workshop lesson plan and hands-on activity to effectively
introduce bone tissue engineering to young students by demonstrating bone
biology and implant development
As detailed in Chapter 2, Aim 1 study was designed to simulate the natural bone
environment, considerations for cell ratio were taken into account to demonstrate the
differences in cellular interaction, communication, and activity. The culture system used
3D ChronOS bone granules (Synthes) to simulate the complex architecture of bone
extracellular matrix. Precursor bone cells were seeded at three RAW:D1 ratios (1:1, 1:10,
1:100) to culture for 35 days under osteogenic condition to monitor cellular
differentiation and activity. Analysis of relative gene expression and protein levels were
quantified to determine which cell ratio follows physiological behavior at key stages of
maturation. Visual observations via fluorescent microscopy confirmed cell attachment,
proliferation, and morphology.
Experimental details for Aim 2, as detailed in chapter 2, was conducted
simultaneously with Aim 1 by including an additional culture condition of osteogenic
medium supplemented with RANK ligand. Osteoblast and osteoclast maturation will be
monitored for relative gene expression and protein production.
Aim 3, detailed in Chapter 3, focused on the multi-cellular culture of osteoclasts
and osteoblasts in the presence of differentiated adipocytes to determine the influence of
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adipocytes on bone cell activity. To simulate direct communication of differentiating
precursor osteoclasts with osteoblasts and indirect communication with adipocytes,
Netwell inserts were used to suspend the co-culture within a well compartment with
adipocytes. Adipogenic differentiation of D1 cells on well-plates began 7 days prior to
tri-culture simulation. Seeding of co-culture of RAW:D1 occurred 3 days prior to triculture for 14 days. Information on cell ratio gleaned from Aim 1 and Aim 2 were
implemented in the experimental setup for Aim 3 in simulating normal bone cell
interactions. By applying the co-culture to the tri-culture system with adipocytes, effects
of adipogenic factors (lipids, hormones) on osteoclast and osteoblast activity were
examined with gene expression and protein production. Behavior characterization
methods for osteoclasts and osteoblasts were duplicated from Aims 1 and 2 with the
addition of adipogenic markers.
The educational outreach workshop from Aim 4, as detailed in Chapter 4,
introduced bone tissue engineering technologies to a group of girl scouts and high school
students through a presentation, a hands-on activity, and an interactive communication.
The teaching module incorporated biomedical engineering, bone biology, and medical
devices for fracture management. The teaching module was implemented during two
separate events with other teaching modules that also focused on introducing engineering
and science to the students. Hence, the biomedical engineering teaching module was
limited to 1-hour. The presentation provided an overview of bone physiology, various
bone diseases, and orthopedic implants ending with a problem statement for the students
to address in their hands-on activity. With the information given to them, the students
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were challenged to strategize, implement, and test a plan to stabilize a simulated normal
fracture and an osteoporotic fracture. Instructions required the girls to follow the
development scheme of brainstorming, designing, prototyping, and testing. The hands-on
activity will be made into a kit consisting of the tools, simulated fractures (cardboard
tubes filled with styrofoam and insulation foam), screws, and a metal or plastic mending
plate as internal fixation screw and plate system. Effectiveness and influence of the
demonstration were measured by social cognitive theory pre- and post- survey questions,
including rank based and open-ended questions. Due to the time constraint for each group
of students, measurements of career interest incorporated engineering, science, and math
in general rather than a focus on biomedical engineering.
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CHAPTER ONE
INTRODUCTION
1.1

Clinical Significance
Tissue engineering and regenerative medicine emerged to resolve shortages in

tissue transplantation for treatment of damaged tissues and organs. The theory is that
engineered biotechnologies incorporating biomaterials, chemical mediators, and stem
cells can produce functional tissues that repair and prevent the loss of damaged tissues.
Many advances have been possible due to increased understanding and discoveries of
human pathology at the tissue to molecular level. Innovations in medicine are driven by
the objective to decrease patient suffering and increase longevity, especially as the
population and life expectancy grow. However, as the past generations age and the future
generations become more active, the frequency of injuries and diseases will increase
dramatically. The Centers for Disease Control has predicted that, in 2020, over 51.5
million people in the United States will be ≥65 years old, while the United States Census
Bureau estimates the world population will reach 8 billion people. The rise in population
will amplify the strain on the medical industry to maintain a healthy population. Since
traumatic injuries can result in tissue or organ failure, tissue transplantation will become a
necessity. There are many complications associated with tissue transplantation and a
major challenge is obtaining viable donor tissue. Consequently, tissue engineering and
regenerative medicine is evolving to develop patient-specific and biologically functional
tissues.
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Bone grafts are the second most transplanted tissues, exceeded only by blood [4].
Currently, over 500,000 bone graft implantations occur annually in the United States,
with surgeons preferentially using gold standard autografts, opting for allografts as a
second choice, to treat large bone fractures and defects. Further considerations of fracture
severity, fracture location (long or flat bone), and bone type (cancellous or cortical) are
required to choose the optimal graft to induce an effective bone healing response [5].
However, autografts and allografts are also the top choices for patients with bone diseases
and impaired healing reactions. Normal healing time for cortical (compact) bones are
much longer than cancellous (spongy) bones due to the differences in bone density, but
bones with impaired healing will, at best, heal at the slowest rate or, at worst, have
incomplete healing. Even though there are limitations to bone grafting, especially for
patients with degenerative bone diseases, both cortical and cancellous autografts and
allografts are used.
Autografts and allografts bridge the gaps at fracture sites to provide skeletal
continuity and encourage the innate bone healing cascade. The transplanted grafts are
considered necrotic tissues that serve as the template for bone regeneration. The bone
healing and repair reactions start with the formation of a hematoma to induce
revascularization and recruit progenitor bone cells to the site of injury within 2 weeks.
Bone cells then form new woven bone to stabilize and establish skeletal continuity at the
fracture, which can take 6 weeks to 6 months. The woven bone is eventually remodeled
into mature lamellar bone, years following the implantation [5, 6]. The rate and success
of bone repair and regeneration depends on the quality and type of grafts transplanted.
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Autologous and donor bone tissue can be cortical (compact) or cancellous (spongy), the
two natural organizations and architectures of bone. Cortical and cancellous graft
transplantations will each induce a different healing response and graft integration with
host bone tissue (osteointegration) [6]. Cortical grafts have low porosity that results in
minimal neo-vascular formation, resorption of the graft before woven bone regeneration,
and remodeling of the graft. Due to the lack of vascular infiltration and density of the
graft, osteointegration is limited to the exterior where surface bone resorption provides
space for woven bone formation. Consequently, 50-90% of residual necrotic graft tissues
remains and can diminish the mechanical integrity of bone at the fracture gap. Cancellous
grafts, on the other hand, have high porosity to induce ingrowth of new blood vessels,
new woven bone, and complete remodeling of the graft in which lamellar bone replaces
both the woven bone and graft material [6]. Clearly, if not for the limited quantity of
autografts and low quality of allografts, the graft of choice is a cancellous graft.
Autografts are bone tissue retrieved from the patient’s own bone through a
surgical extraction procedure, most commonly at the iliac crest. It is thought that
transplantation of the bone will provide viable tissue with biological function; however,
the removal will damage the cellular components, tissue continuity, and the tissue’s
regenerative ability. Compared to allografts and donor bone tissue, autografts increase
patient risk during extraction procedures but have enhanced graft-to-tissue integration
(osteointegration) and compressive strength. The autograft harvesting causes
complications in 8-20% of all patients, including blood loss, nerve damage, artery
damage, chronic pain, tissue necrosis, and infection [4]. For patients with bone disease,
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autograft extraction and implantation significantly increases healing complications due to
decreased bone quality and regeneration ability; hence, allografts are the alternative of
choice.
Allograft is donor bone tissue that has been processed to remove all cellular,
bacterial, and viral components to eliminate immune response and disease transmission
[7]. Even though processing significantly compromises osteogenic and mechanical
properties of the tissue, it is the material of choice for 35% of all grafting procedures
because of its availability, shelf-life, and customizable type and size [8]. The
physiochemical properties of allografts are different for fresh, frozen, or freeze-dried
allografts. Fresh allografts are rarely used because of the extended time required for
screening to prevent disease transmission. Processed allografts can be frozen at -60°C or
freeze-dried to decrease enzymatic activity and immune response or destroy all cellular
components and completely eliminate immune responses. These processing methods
decrease the tissue’s ability to recruit progenitor bone cells (osteoinduction) and to
mediate differentiation of bone cells. However, with the introduction of bone
morphogenic protein (BMP) into allografts, a 15-fold increase in allograft implantation
occurred over the past decade [4, 9].
With the increased frequency of bone fractures and with the low and costly
allograft supply, surgeons are more frequently opting for bone substitute materials. The
development of substitute biomaterials for bone constructs will allow customizable
mechanical and biological properties native to bone. Eventually, enhancements will
incorporate osteoinductive and osteoconductive properties for constructs, specifically for
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mediating bone healing in diseased bone. Synthetic and natural biomaterials with
physicochemical properties similar to the inorganic and organic components of bone are a
focus of ongoing investigation. The design and construction of a temporary 3D template
that mimics the inherent architecture and compressive strength are ongoing challenges
within the evolving field of bone tissue engineering. Furthermore, the future direction of
substitute bone construct design and development should target fragility fractures in
diseased bone.
1.2

Background in Bone Tissue Engineering
Before regenerative medicine and bone grafts were developed in widespread

form, large segmental bone defects lead to amputations. However, recent advances in
fixation devices, bone tissue engineering, and surgical procedures have lead to restoration
options for bone and limb tissue [9]. The first documented bone tissue engineering
attempt was in 1668 when bone grafting was first attempted and evolved into a
multidisciplinary science that has facilitated the development of biotechnologies and
management procedures for treating various bone defects and diseases [6]. By
investigating mechanisms of bone pathology, researchers are able to map physiological
repair and remodeling reactions and pathways in bone metabolism. A thorough
understanding of bone tissue and bone remodeling is essential to designing regenerative
solutions that maintain bone integrity and target degenerative bone diseases.
1.1.1

Bone Composition and Structure
At the surface, bone looks simple and non-viable but at the microscopic level the

complexity and dynamic nature of bone matrix and bone cells are evident. Bone tissue
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harnesses an innate ability to self heal from micro- and macro-fractures throughout a
person’s lifetime, while providing structural mechanics, movement, and protection. The
206 bones in the body assemble into an upright skeleton to support and protect all other
soft tissues. The irregular shapes of bones have been optimized for ease of movement at
each joint, transmission of external loads, and protection for each vital organ. Bone is
composed of inorganic (hydroxyapatite) and organic matrix (collagen and proteoglycans)
organized into a 3D structure of Haversian and Volkmann canals.
The architectural organization of bone can be classified into cancellous and
cortical, according to structural density and porosity. Bone matrix is a combination of
highly compressive hydroxyapatite, crystalline and highly ductile collagen, and
proteoglycans; this combination allows the tissue to withstand varying loads of tension,
compression, and shear encountered by the body. To further reinforce structural integrity,
the matrix is arranged into parallel or circumferential lamellae to form cancellous or
cortical bone, respectively. Due to the longitudinal organization, bone is an anisotropic
material with higher resistance to longitudinal forces than latitudinal.
Cortical bone serves as the outer lining for most bones because it is stronger and
heavier than cancellous bone. This highly compact bone with <10% porosity is made of
longitudinal concentric lamellae (layers), with interstitial and circumferential lamellae for
compressive strength and load transmission. Within compact matrix, there is a network of
Haversian and Volkmann canals through which vascular structures pass, as well as
lacunae-containing osteocytes (mature bone cells). The compressive modulus of cortical
bone is ~17.0 GPa in the longitudinal direction, ~11.5 GPa in the transverse direction,
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and ~3.3GPa in shear [10]. Cancellous bone, on the other hand, has a parallel lamellar
organization that forms interconnected struts called trabeculae. Enclosed by cortical bone,
the trabecular organization of cancellous bone has a density range of 5-90% depending
on location, resulting in much lower weight and compressive moduli of 291-445 MPa.
However, these lightweight struts serve to redistribute load more effectively along the
bone while the interconnected pores store bone marrow and a vascular network [10].
These two types of bone are then arranged in various configurations to form long
segmental, flat, or irregular bones and serve their specific function of locomotion or
protection. Since bone is a living tissue, it is composed of specialized cells with innate
capacities to maintain bone integrity by continually remodeling old bone and repairing
damaged bone.
These structural organization and mechanical properties are challenging to
integrate in bone substitute constructs due to material and fabrication limitations of
current technologies. Innovative bone construct designs have included hardened sponges,
sintered microspheres, fibrous matrices, and rapid prototyped woven matrices [11-16].
1.1.2

Bone Cellular Components
At the core of hollow long bones lies bone marrow, a source for skeletal

progenitor cells that have been shown to differentiate along osteoblastic, adipogenic, and
chondrogenic lineages [17]. Friedenstein and coworkers discovered bone marrow during
their investigation of bone’s innate healing capacity as related to stem/progenitor cell
involvement and availability [17-19]. Further characterization of heterogeneous mixtures
of bone marrow stem and progenitor cells has lead to understanding the differentiation
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Figure 1.1. Differentiation of osteoblasts (A) and osteoclasts (B) in response to
internal cytokines and molecular mediators.

potential of the multipotent adult progenitor cells, mesenchymal stem cells, bone marrow
stromal cells, and hematopoietic stem cells [17].
The cellular components of bone are under highly regulated coordination in
response to internal signaling and external mechanical loading. The resorption and
production of bone matrix are the results of activated osteogenic cells, differentiated from
mesenchymal stem cells (MSC) and hematopoietic stem cells in response to cytokines
and growth factors (Figure 1.1). Recruited hematopoietic stem cells, specifically
monocytes, are directed by macrophage colony stimulating factor (M-CSF), receptor
activator of NFĸ (RANK), and RANK ligand (RANKL) to fuse into inactive
13

multinucleated osteoclasts. Further interactions of RANK, a surface receptor of
osteoclastic cells, and RANKL, a surface marker of osteoblasts, will polarize osteoclasts
to develop resorptive ruffled borders that attach to the bone matrix. The ruffled borders
enclose an area marked for resorption and the secretion of protolytic enzyme cathepsin K
and tartrate-resistant acid phosphatase (TRAP) for the degradation of the unwanted bone
matrix. However, osteoprotegerin (OPG) serves as the negative feedback that interferes
with RANKL and RANK signaling to inhibit and regulate osteoclast polarization and
activation. The enzymatic resorption process creates pits on the bone surface called
“Howship’s lacuna”, which are coated with cytokines and factors to recruit osteoblastic
cells to the excavation site to deposit new bone at the eroded surface [1]. Osteoblasts
differentiate from mesenchymal stem cells, with transcription factor signaling via Runx2,
osterix, and β-catenin. The progenitor cells differentiate into preosteoblasts, then
immature osteoblasts, expressing high levels of osteopontin. Osteoblast maturation
continues under the control of Runx2. During this time the mature osteoblasts release
high levels of alkaline phosphatase (ALP) and express osteocalcin, as mineralization
occurs and new bone matrix is deposited [20]. As new extracellular matrix composed of
the inorganic and organic phase of bone accumulates, osteoblasts become embedded
within the matrix, leading to their differentiation into osteocytes; subsequently, these
cells remain latent in the lacunae to monitor the health of the bone. Osteocytes are able to
communicate and interact directly with vasculature and other osteocytes because of their
numerous cytoskeletal extensions that travel along microscopic channels called canaliculi
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[1]. Consequently, when there is a disturbance in bone integrity, osteocytes initiate bone
healing reactions.
A recent discovery of fatty acid secretions mediating bone mineral density has led
investigators to study the influence of adipocytes, or fat cells, on bone formation [21, 22].
Adipocyte secretions have been shown to regulate the activity of both osteoclasts and
osteoblasts. Adipocytes are found in close proximity to bone cells in brown and white
marrow fat and their fatty acid secretions can diffuse into active bone cells undergoing
bone remodeling. Studies have shown that stearic and palmitic acids decrease the
expression of alkaline phosphatase (ALP), which is an indicator of osteoblast
mineralization, while linoleic acids increase the expression of ALP [21, 23]. However,
fatty acids such as dexamethasone and prostaglandin E2 promote osteoclast resorption.
This regulation by fatty acids establishes a direct relationship of aging bone with
increased fatty marrow to low bone mineral density in geriatric patients [24].
As bone cells differentiate under high regulation, favorable conditions, and
mediators, bone remodeling and healing will proceed with a balance in bone degradation
and deposition for optimal bone integrity and health. Unfortunately, traumatic injuries
and cellular imbalances occur which challenge the innate self-healing capacity and the
regulated feedback mechanisms, respectively.
1.1.3

The Bone Healing Process and Bone Cell Communication
Bone is the infrastructure of the body, possessing mechanical and biological

properties vital for support, protection, growth, and immunity. However, like most tissues
in the body, bone has a physiological carrying capacity, namely its mechanical strength.
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When skeletal continuity is disrupted due to excessive stress and loading, bone can repair
and heal itself without producing a scar. The physiological healing process is extensive,
involving a vast network of cellular signals to recruit and differentiate progenitor stem
cells to osteoclasts and osteoblasts in order to resorb and deposit new bone [25]. Since
bone serves as the structural support for the body, healing and repairing reactions are
impacted by the mechanical stability and the biological environment of the damage or
fracture site, along with the severity of injury of the surrounding soft tissues. After an
assessment of the damage, primary or secondary healing reactions will occur.
Primary fracture healing via a “cutting cone” occurs with absolute stability,
requiring no external callus bridging. However, if the fracture gap exceeds 200µm,
osteoclasts are hindered from constructing the “cutting cone”, which can delay bone
union. The “cutting cone” is the organization of osteoclasts that tunnel across the fracture
line to resorb bone while osteoblasts are recruited to deposit new bone and reconstruct the
bone union [5]. For secondary bone healing, there is a strain between the fracture surfaces
that necessitates the formation of a callus bridge to stabilize the fracture for ossification.
This type of healing is typical for patients with bone graft implantations and/or internal
fixation devices. There are four phases to secondary healing, all of which are regulated at
the cellular and molecular level for neo-vascularization and bone regeneration. The
process starts with non-specific signaling to respond to the trauma-related inflammation
and hematoma formation, proceeds to fracture bridging via soft callus, then to hard callus
formation, and finally to specific regulation of bone remodeling [1, 5, 25-29]. Even
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though the repair process is highly regulated, participating cellular and molecular
components contribute at each phase, overlapping as seen in Figure 1.2.
Phase 1: Inflammation
Fractures due to trauma also result in disruption of the surrounding tissues, vasculature,
and bone integrity. This trauma causes an immediate, nonspecific response in which the

Inflammatory cells
Chondrocytes
Mesenchymal stem cells

Osteoblasts

Hematopoietic stem cells

Osteoclasts

Vascular cells
Phase 1:
Hematoma formation

Phase 2:
Callus formation

Phase 3:
Hard callus formation

Phase 4:
Remodeling

Figure 1.2. Timeline of cellular contributors during the four phases of bone remodeling. (Adapted from
Schindeler et al., 2008, and Carano and Filvaroff [1, 2]).

pooling of blood and accumulation of inflammatory cells at the injury site form a
hematoma encased by surrounding tissues. The inflammatory cells, such as degranulated
platelets, macrophages, monocytes, and lymphocytes, are the first responders to form a
blot clot and remodel the hematoma into granulation tissue as macrophages and giant
cells remove necrotic cells. Cellular coordination is conducted through the secretion of
cytokines and growth factors, such as vascular endothelial growth factors (VEGF),
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platelet-derived growth factor (PDGF), and others seen in Table 1.1, to mediate
recruitment of more inflammatory cells as well as chondrogenic and osteoprogenitor cells
[1, 29].
Table 1.1. Molecular Contributors to Bone Healing
Pro-inflammatory cytokines
and growth factors

Pro-osteogenic factors

Angiogenic factors

Transforming growth factor-β
(TGF-β)

Runt-mediated transcription
factor (Runx2)

VEGF

Platelet-derived growth factor
(PDGF)

Receptor activator of NFκB
(RANK)

BMPs

Fibroblast growth factor-2
(FGF-2)

RANK ligand (RANKL)

FGF-1

Vascular endothelial growth
factor (VEGF)

BMPs

TGF-β

Macrophage colony stimulating
factor (M-CSF)

M-CSF

Angiopoietin I and II

Interleukin-1 and -6 (IL-1, IL6)

Osteoprotegrin (OPG)

Bone morphogenetic proteins
(BMPs)
Tumor necrosis factor-α
(TNF-α)

Phase 2: Soft callus (fibrocartilage) formation
Once chondrogenic and fibroblastic cells reach the bone fracture, endochondral
ossification occurs as a fibrocartilage soft callus is formed. Since the fracture site is
mechanically unstable, a soft callus provides stability and a template for primary bone
formation. Recruited mesenchymal progenitor cells differentiate into chondrocytes to
produce the cartilaginous matrix that merges with fibrous tissue produced by fibroblasts
to establish a continuous bone bridge [1]. Bone morphogenetic protein and fibroblast
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growth factor (FGF) are the major signaling molecules for ossification [30].
Angiogenesis, or the formation of new blood vessels, occurs concurrently with
ossification under the control of VEGF and angiopoietin I and II [26]. However, VEGF
expression is dependent on the expression of Runx2 (early osteoblastic marker) by
osteogenic cells activated for hard callus formation [1].
Phase 3: Hard callus formation
This phase is the major component of osteogenesis and includes a high level of
osteoblast matrix deposition onto the soft callus template, following which the
mineralized bone matrix converts the soft callus into a hard callus or woven bone.
Activated osteoblasts are recruited with osteogenic factors from the super family of
transforming growth factor-β (TGF-β), such as BMP-differentiating osteoprogenitor cells
recruited during hematoma formation. With the help of vascular networks,
osteoprogenitor cells and their differentiation signals are able to infiltrate the soft callus
to efficiently mineralize the woven bone [1, 30]. However, innate bone repair continues
to reestablish structural organization of native bone and converts woven bone into
lamellar bone.
Phase 4: Bone remodeling
The conversion to lamellar bone requires resorption of woven bone by osteoclasts.
Osteoclasts differentiated from monocytes remodel the woven bone hard callus into
lamellar bone in the appropriate cortical or cancellous configuration. Monocytes are first
recruited to the site for remodeling, then the cells mature into polarized osteoclasts and
adhere to the mineralized surface. The attached ruffled borders of osteoclasts secrete
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proteases such as cathepsin K and tartrate-resistant acid phosphatase (TRAP) to degrade
the woven bone. The resorption process creates pits on the bone surface called
“Howship’s lacuna” that recruit and activate osteoblasts to regenerate new bone at the
eroded surface. Cytokines such as macrophage colony stimulating factor (M-CSF)
regulate osteoblast bone mineralization, while receptor activator of NFĸ (RANK) and
RANK ligand (RANKL) activate osteoclast resorption and osteoprotegerin (OPG) to
inactivate resorption as needed [1, 25, 29, 31-33]. The bone remodeling phase is a
juxtaposition of osteoblast anabolism and osteoclast catabolism of bone matrix [1].
The four phases of bone healing occur in conjunction with each other with no real
separation between the end of one phase and the start of another. The balanced reaction is
highly regulated and coordinated at the cellular and molecular level to produce effective
healing responses. Healing rates are dependent on the implanted grafts (cortical or
cancellous), the health of the patient, and location and severity of the fracture.
1.3

Bone Pathology
Bone healing reactions of adults and children suffering with bone diseases and

defects are compromised, leading to complications with graft implantation and internal
fixation treatments. When imbalances occur within the highly regulated bone repair and
remodeling processes, bone diseases arise from abnormal bone cell activity and
metabolism. The majority of bone diseases are due to overactive or inactive osteoclasts,
resulting in decreased bone density or increased bone mass, respectively. The most
diagnosed bone disease is osteoporosis, or low bone density, a degenerative disease
affecting the aged population. The onset of osteoporosis is osteopenia, or the gradual loss
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of bone mass associated with high osteoclast resorptive activity exceeding osteoblastic
regenerative activity [34]. Risk factors for developing osteopenia and osteoporosis
include low physical activity and vitamin D deficiency, which are physical and chemical
stimulators for bone remodeling. The combination of aging and low physical activity will
increase osteoporosis risk, since factors will increase marrow fat concentration which can
interfere with osteoblast activity while promoting osteoclast metabolism [35-37]. Johnell
and Kanis estimated the world burden of osteoporotic fractures to be 9 million
occurrences in the year 2000, with 61% affiliated with women over the age of 50. The
most common fractures incurred by osteoporotic patients are vertebral fractures which
can be fatal if not debilitating [38]. Current pharmaceutical agents for osteoporosis target
and interfere with RANK/RANKL and/or induce the OPG signaling pathway to prevent
osteoclastogenesis (osteoclast differentiation and activation) [3].
At the other extreme, impairment of osteoclast resorption or osteoclastogenesis
will result in osteopetrosis, sclerosteosis, or Paget’s disease conditions, i.e. high bone
mass due to osteoblastic bone matrix construction in the absence of osteoclastic bone
matrix destruction [3]. Osteopetrosis is a rare hereditary genetic disease, involving
osteoclastogenesis inhibition and associated low supply of bone marrow, osteosclerosis,
short stature, brittle bones, and even cranial nerve compression due to the closure of the
cancellous bone cavities [39, 40]. Sclerosteosis is caused by interference of
osteoclastogenesis via the Wnt signaling pathway that regulates production of RANKL
and OPG in osteoblasts [3]. The dense bone mass in Paget’s disease is due to accelerated
bone remodeling in which bone formation compensates for increased resorption from
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hypersensitive osteoclasts [40]. Even though bone mineral and matrix are dense in these
disease states, bone fragility increases since the disorganized accumulation of bone will
lead to decreased mechanical strength and structural integrity.
Osteogenesis imperfecta is another genetic bone disease affecting the
differentiation of mesenchymal stem cells into osteoblasts to produce collagen Type I, an
important matrix component of bone that provides tensile strength. Patients with
osteogenesis imperfecta have bone fragility leading to multiple fractures, skeletal
development retardation, and skeletal deformities. This disease can affect all age and
gender groups and currently no cure is available. Bisphosphonates are the only known
broad-spectrum treatment for mild cases; however, in severe cases, especially in children,
bone marrow transplants are common [41]. Adults with osteogenesis imperfecta can also
have osteoporosis and threefold higher risk of fractures [42].
Metastatic bone disease occurs in cancer patients; breast and prostate cancer
patients have the highest risk, due to radiation chemotherapy and hormonal therapy [43].
For example, breast cancer cells express runt-mediated transcription factor 2 (Runx2),
which is also a master transcription factor for osteoblast differentiation. Runx2 promotes
the osteoblast lineage in the differentiation of mesenchymal stem cells into immature,
then mature, osteoblasts. Consequently, mutations of Runx2 are associated with bone
cancer (osteosarcoma), with undefined pathological mechanisms afflicting children and
young adults, especially during growth spurts [44, 45]. Management of metastatic bone
disease and osteosarcoma involves chemotherapy and bisphosphonate therapy to inhibit
the growth of cancerous bone cells [45, 46].
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The pathological environment of bone diseases alters not only bone cell activity
but also morphology and concentration of osteoblastic and osteoclastic cells. In
examining the limited histomorphometric studies, the range of precursor bone cell ratios
for physiological and bone diseases was determined (Table 1.2)[47-50]. The table lists
number of osteoclasts and osteoblasts per millimeter of bone perimeter, following the
standard of histomorphometry from the American Society for Bone and Mineral
Table 1.2. Bone Cell Number via Histomorphometric Analysis of Bone Biopsy
Osteoclast
Osteoblast (OB)
OC:OB
Location
Reference
(OC)
Pestka. Eur
Control
0.26±0.15mm-1 4.03 ± 1.30 mm-1
1:15.5
Vertebra
Spine, 2012.
VukmirovicControl
0.10±0.1mm-1
1.5 ± 0.30 mm-1
1:15
Femor
popovic. Bone,
2002.
Rauch. Bone,
-1
Control
0.35±0.18mm
Iliac crest
2000.
Rauch. J of Bone
Control
0.30±1.68mm-1
Iliac crest
and Mineral Res,
2000.
Paget’s Disease
Bone Metastasis
Breast
Carcinoma
Osteogenesis
Imperfecta I
Osteoporosis

0.92±0.33mm-1

21.27±10.51mm1

1:23.1

Vertebra

1.7±0.5mm-1

2.7±0.5mm-1

1:1.6

Femur

0.47±0.29mm-1

-

-

Iliac crest

0.20±2.04mm-1

-

-

Iliac crest

Pestka. Eur
Spine, 2012.
Vukmirovicpopovic. Bone,
2002.
Rauch. Bone,
2000.
Rauch. J of Bone
and Mineral Res,
2000.

Research. From the number of osteoclasts and osteoblasts per bone surface, the cell ratio
was calculated. The ratios indicate a range of variability in the disease state, a key finding
for simulating pathological bone environment in co-culture. Furthermore, histology
shows morphology differences, as compared with normal cells, in osteoclasts and
osteoblasts involved in Paget’s disease. Advances in understanding the cellular etiology
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of common and rare bone diseases will demonstrate the morphological abnormalities and
concentration differences of osteoblastic and osteoclastic cells.
For patients with bone diseases, the inherent increased risk of bone fractures is
dramatic, including increased complications in fracture healing and management. These
patients must take a high number of precautions during everyday activities and avoid the
fundamental causes of fracture.
1.1.4

Causes of Fractures
Patients suffering from bone diseases are more likely to incur a bone fracture due

to the compromised mechanical properties of their bones. When bone experiences tensile
or compressive stresses (cyclic or direct) that exceed the limits of normal bone strength, it
will fracture. Bones that fracture under normal physiological stress and loading are
diseased bones with reduced mechanical and physicochemical properties. The anisotropic
mechanical strength of bone (high longitudinal strength, low latitudinal strength) means
that bone will most likely fracture into multiple fragments under extreme perpendicular
and rotational stresses. Fractures can have different levels of severity, from a minor
micro-crack that goes unnoticed to a major open fracture with a break in the skin and
damage to the surrounding tissues or organs. Fracture types or patterns are classified as
[5]:

•

Complete or incomplete

•

Displaced or undisplaced

•

Simple or comminuted

•

Open or closed
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Each classification has subcategories so that all details of the fracture are
accounted in order to choose the most effective treatment and management solutions.
However, an important indicator for intervention options is the patient. Physicians must
consider the patient age, health condition, type of trauma, site of fracture, bone type, and
fracture type.
In the case of osteoporotic fractures, prevalence of fractures in the spine and
proximal femur are higher in older patients as compared to younger patients, with high
risk for distal radial fractures. Vertebral fractures in osteoporotic patients occur under
normal body weight and will cause deformities of the spine and chronic back pain.
Management of spinal fractures includes use of bone grafts and fixation devices for
spinal fusion to redistribute load, while femoral fractures are immobilized by
intramedullary nails or plates to induce bone healing.
Since bone fractures are more prevalent in patients with bone diseases,
pharmacological treatments targeting specific remodeling processes will suppress healing
reactions at the fracture site. This suppression will lead to high rates of non-unions for
this category of patients [30, 51]. The juxtaposition of inhibitory protective agents and
fracture healing has little consideration in the management of bone fractures and the
development of substitute bone. Hence it is important to review the advances and gaps
with respect to implementation of pharmaceutical agents and bone substitute materials for
fracture healing in diseased bone.
1.4

Review of Advances in Bone Tissue Engineering and Regenerative Medicine

25

1.1.5

Clinical Approaches to Bone Diseases and Defects
Expanding knowledge of bone abnormalities has enabled innovative diagnosis

capabilities, surgical procedures, and therapeutic solutions. Clinical approaches focus on
bone protective therapy for the aging population and cancer patients with osteoporosis
and bone metastases, respectively. The majority of therapeutic medicines for bone
diseases disrupt the osteoclastic (anti-resorptive/anti-catabolic) pathway and promote the
osteoblastic (pro-anabolic) pathway [3]. Fracture management surgical interventions for
diseased bones are limited to solutions designed for healthy bone with normal bone cell
activity.
Pharmacological therapies targeting abnormal cell signaling in benign and
malignant bone diseases can provide effective solutions but have complicated side effects
[52, 53]. For example, bisphosphonates are a broad spectrum class of drugs used for
many osteoporotic types to inhibit resorptive activities; however, the side effects can
include renal dysfunction, gastrointestinal complications, or even osteonecrosis of the jaw
[3, 46, 54]. Other studies have revealed the benefits of bisphosphonates, which have
apparent anti-tumor effects when administered to cancer patients suffering from
osteolysis or which, in combination with chemotherapy, inhibit the growth of
osteosarcoma cells [45, 53]. Bisphosphonates are also administered to osteoporotic
patients with total hip replacements to prevent aseptic loosening and peri-implant
osteolysis [55]. Denosumad is an anti-resorptive pharmaceutical agent targeting RANKL
signaling in osteoclast activation; a clinical study showed the agent’s anti-fracture
efficacy for women with postmenopausal osteoporosis, i.e. reduced fracture incidence in
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vertebrae and increased bone mineral density in the hip [3]. Other bone-modulating
agents target the protolytic enzyme cathepsin K, the Wnt pathway (indirect RANKL and
OPG regulation), and calcium-sensing receptors to downregulate hormonal stimulators
(parathyroid hormone) in bone remodeling [3, 25]. These agents are only medicinal
therapies that prevent disease exacerbation; they do not prevent bone fragility and risk for
painful fractures.
Surgical intervention is used to stabilize fractures in healthy bone with internal
fixation devices and bone substitutes, providing a mechanically favorable environment
and template for bone healing. For fractures in long bones, like the femur and humorous,
implanted fixation devices provide rigid stability using screws and plates; bone
substitutes are sometimes used to bridge the fracture gap. The traditional screws and
plates are also used for the fixation of osteoporotic fractures in which the stability of the
device depends on the integration of the screw to the bone. However, the stability of the
traditional fixation system is compromised by the low bone mass in osteoporotic bone.
Consequently, implant loosening and progressive instability will cause nonunions at the
fracture gap [56]. Proximal femoral fractures in older patients are treated with urgent
attention to control of bleeding and to achieve successful fixation and minimize future
complications. In bone metastatic diseases, surgical intervention is intended to control
tumor growth and provide load-bearing capabilities to the defective area [57]. Insufficient
recognition of compromised bone mechanics in diseased bone has lead to implant failures
and increasing patient suffering [58]. However, efforts towards redesigning the screw and
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plate systems for low quality bone have been ongoing with products such as angular
stability screws and plates, and bicortical screws [56, 58, 59].
Fracture management also depends on the enhancement of fracture healing with
autografts and allografts. The practice of graft implantation has grown in the past two
decades, as indicated by the $300 million market in 1999, to an astounding $1.6 billion in
2008 as estimated by the Orthopedic Network News [60]. Bone grafting procedures are
predominantly performed in the spine (80%), with combinations of bone morphogenic
protein to encourage regenerative bone fusion. The incorporation of BMP was one of the
first approaches to bone tissue engineering; many advances have been achieved to
enhance bone healing and formation, with some focus in bone diseases.
1.1.6

Bioactive and Regenerative Advances
The transition into regenerative practices is evident in the rise of bone substitute

purchases of 28.6% in 2006 to 51.6% in 2007, in conjunction with the ~12% increase in
BMP purchases [60]. The shift in focus is an effort to explore promising pathways of a
functional bone substitute via cellular factors, chemical factors, and molecular factors to
stimulate bone regeneration, even in abnormal bone conditions. The use of autologous
bone marrow and its cellular components with bone substitutes is an emerging alternative
to enhance osteogenicity and osteoconductivity [61]. Bone substitutes can also be carriers
for disease-targeting macromolecules in the anti-catabolic and pro-anabolic pathways for
local delivery [62]. Other strategies combine the effects of systemic bone protective
agents with local delivery of molecular osteogenic factors [63]. Innovative development
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of functionalized substitute bone has the capacity to resolve the rising demand for bone
tissue transplantation in the aging population due to the rise in bone diseases.
The bone substitute construct or scaffold serves as a temporary template for
cellular recruitment, differentiation, and matrix deposition in bone regeneration and
provides continuity in mechanical stability at the defective area. The strategy of using
functionalized bone scaffolds focuses on stimulating and directing all four phases in the
bone healing reaction. The functionality depends mainly on the biomaterial of choice and
the retention of potency and efficacy of the supplements within the defect bone.
Fabricating a sophisticated biomaterial that can mimic the innate regenerative
capacity of bone tissue is a challenge. Strategies incorporating biomimetic bone scaffolds
have focused on the use of bone marrow and platelet rich plasma to enhance
osteoinductive properties of substitute bone grafts in an intraoperative procedure [61].
Researchers have infused anti-anabolic and pro-catabolic agents and molecular factors to
stimulate bone cell activity in various bone scaffolds [64].
Cellular Factors: Bone Marrow
Bone marrow is a source for osteoprogenitor and hematopoietic stems cells;
therefore, cellular grafting of autologous marrow aspirate is of high interest for enhancing
fracture unions [63, 65]. Bone marrow has been used in its entirety and in fractions,
depending on the bone defect. Various methods of bone marrow extraction have been
evaluated to isolate marrow stromal cells, mesenchymal cells, hematopoietic stem cells,
and even marrow fat cells [61, 66]. Whole bone marrow transplants are commonly
performed for genetic bone diseases such as osteopetrosis and osteogenesis imperfecta in
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order to replace abnormal bone cells with normal cells. As for alveolar bone defects in
the maxilla, allografts are pre-soaked in bone marrow before implantation to mediate
enhanced bone healing [67, 68]. In long bone fractures, intramedullary nails are
implanted into the canal of the long bone to provide rigid stability for enhanced union.
The implantation of the intramedullary nail requires the surgeon to ream the bone canal,
which generates reamed aspirate that is filtered and divided into intraoperative
autologous osseous particle and filtrate waste. The osseous aspirate material containing
bone fragments is placed onto the defect to enhance osteoconductivity of the allograft or
bone substitute bridging the fracture gap [69, 70].
However, the waste filtrate or the liquid flow-through from the reaming process is
of high interest for its osteogenic potential with cellular components and various growth
factors involved in bone metabolism [65]. Porter and coworkers confirmed that the
filtrate had growth factors such as PDGF, VEGF, and TGF, along with multipotent cells
expressing an MSC phenotype [65, 71]. This conservative approach to re-incorporate the
filtrate will further enhance the osteoinductive environment of the allograft and bone
scaffold.
Current intraoperative enhancements of allografts and commercially available
bone substitutes using whole bone marrow can have complications. The recent discovery
that adipocytes found in bone marrow regulate osteoblast bone formation and osteoclast
bone resorption through fatty acid and hormonal secretions may explain the prevalence of
osteoporosis in geriatric patients since marrow fat increases as bone ages [35]. The use of
bone marrow cellular components refined for optimal bone formation and resorption can
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be of benefit. However, bone marrow and its components are limited in quality, and even
quantity, depending on the patient and the marrow extraction procedure [70].
Chemical Factors: Protective Biomolecules
An alternate treatment should be chosen for patients with bone diseases, who are
incompatible for marrow transplants since the abnormal potential of autologous marrow
stem cells could result in non-union healing. In these instances, strategies of

BHQ-880

AMG-765

Wnt Signaling

Dickkopf-1

Sclerostin

Denosumab

Bisphosphonate

Odanacatib
Rho/Rab

RANKL

Cap K

Osteoblast
Osteoclast

Figure 1.3. Bone protective agents targeting specific osteoblast anabolic and osteoclast catabolic
activities to improve bone quality and prevent disease acceleration. Adapted from [3].

incorporating and loading bone-protective agents within the bone substitute for local
delivery are more advantageous [62, 72, 73]. Current understanding of the exact
mechanism, release rate, degradation, and dosage of the biomolecule in the scaffold is
limited, and future work should include in vitro or in vivo simulations to understand the
interactions at the cellular and system level [74].
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Table 1.3. Bone Protective Agents
Name
BHQ-880
AMG-765
Denosumab

Activity
Inhibits dickkopf-1 from interfering with Wnt signaling to promote bone
formation
Inhibits sclerostin from interfering with Wnt signaling to promote bone
formation
Inhibits RANKL and RANK signaling to prevent osteoclast activation

Bisphosphonate

Inhibits Rho and Rab signaling for osteoclast survival and activity

Odanacatib

Inhibits cathepsin K (Cap K) production of degradation lysozyme

Pharmacological agents used to treat bone diseases target specific signaling
pathways within bone cell differentiation and activity (Figure 1.3 and Table 1.3). These
biomolecules act to neutralize the inactivity of osteoblasts and hyperactivity of
osteoclasts commonly found in osteoporosis for a more effective and accurate induction
or inhibition, with limited side effects. Bisphosphonates are currently the most widely
used protective agents, due to their approved status for treating osteoporosis, the most
common bone disease. Consequently, strategies for loading protective biomolecules
concentrate on incorporation of bisphosphonates, mainly in soluble calcium phosphatebased scaffolds and bone cement [73, 75, 76]. Faucheux and coworkers demonstrated that
zoledronate, a potent bisphosphonate, loaded on calcium phosphate inhibited osteoclast
activity without affecting osteoblast activity [77]. With local inhibition of osteoclast
activity, investigators speculate that the initial application of the drug encourages bone
formation within the bone scaffold, then allows osteoclast resorption to remodel the bone
scaffold and woven bone. Further development is still needed to determine the precise
release kinetics, loading efficacy, and distribution zone, while conserving the integrity of
the bisphosphonates for an optimal bioactive scaffold. As more anti-catabolic and pro-
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anabolic pharmaceutical treatments become available, strategies for different local drug
delivery systems will evolve to allow the development of functional bone scaffolds
specific to various bone diseases.
Molecular Factors: Cytokines, Steroids, and Growth Factors
A more direct approach is to deliver the molecules orchestrating bone resorption
and formation reactions with the bone scaffolds. Some investigators have loaded
cytokines, steroids, and growth factors to emphasize anabolic or catabolic activity during
the phases of bone healing. To initiate phase 1 of the bone healing reactions, platelet-rich
plasma, a source for platelet-derived growth factor and transforming growth factor, has
demonstrated its ability to activate inflammation and coagulation for recruitment of
progenitor and stem cells [63, 78, 79]. Since the discovery of recombinant human BMP-2
and BMP-7 to promote osteoblast differentiation, the use of allografts loaded with BMP
has increased for spinal fusion and tibial fracture repair. Li and coworkers developed a
method to load BMP-2, using gelatin microspheres, into macroporous calcium phosphate
cement for controlled release with enhanced osteoinductivity [80]. The efficacy of BMP
in long bone fractures is still under investigation; hence, there is an ongoing search for
alternate proteins to stimulate good bone healing reactions. Miller and coworkers have
investigated an intraoperative approach to incorporate dexamethasone, a synthetic steroid
stimulating differentiation of MSCs into osteoblasts, with bone aspirate to mediate
reclaimed progenitor cells towards osteoblastic commitment [81]. Another approach by
Arrighi and coworkers was to immobilize active fragments of parathyroid hormone
(PTH) on fibrin matrices for local delivery, to increase bone turnover without systemic
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side effects [82]. Parathyroid hormone treatments have been used for osteoporosis
treatment to maintain calcium homeostasis in bone for indirect regulation of bone
turnover; however, PTH is a broad-spectrum mediator of other metabolic activities in
which a systematic exposure would produce additional complications [63].
With increased sophistication of bioactive scaffolds, design challenges and
constraints will increase. Variability of the bone substitute will increase due to the
incorporation of cellular, chemical, and molecular factors. Preservation and retention of
bioactive structure and potency can be insufficient due to material processing and
scaffold construction. Consequently, with limited pharmaceutical agents approved for
clinical use, a collaborative effort from bone tissue engineering, regenerative medicine,
and pharmaceutical sciences is necessary to investigate synergistic approaches for a
bioactive bone substitute scaffold for treatment of fragility fractures in patients with bone
diseases.
1.1.7

Bone Substitute Biomaterials and Constructs
The basis for a sophisticated bone scaffold is the biomaterial that embodies the

mechanical and physiological properties of the scaffold. Substitute bone constructs must
provide skeletal continuity with mechanical integrity to transmit load, biological
compatibility to avoid immune response, nontoxic degradation to allow new bone
replacement, and mediators to encourage bone healing, even in unfavorable environments
of diseased bone. Materials of choice include ceramics, natural polymers, synthetic
polymers, and their composites. Bone tissue engineers will use biomaterials to engineer
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bone substitute constructs that can mimic aspects of native bone to bridge the fracture gap
as a temporary 3D template with regeneration potential.
Ceramics are the most commonly used materials in bone fracture repair because
of their compressive strength and abundant supply; additionally, the solubility of calcium
phosphate and hydroxyapatite compliments that of common bone protective agents.
Commercially-available bone substitutes, listed in Table 1.4, are mainly based on
Table 1.4. Commercially-Available Bone Substitutes
Company

Product

Material

Biomet Spine

Pro-Osteon

Hydroxyapatite over a calcium carbonate core

Orthovita

Vitoss

β-Tri-calcium phosphate (β-TCP)

Smith & Nephew

Jax Bone Void

Calcium sulfate

Sofamor Danek

MasterGraft Mix

β-TCP and hydroxyapatite

Stryker

HydroSet HA Bone
Calstrux

Calcium phosphate cement
β-TCP granules and carboxymethylcellulose

Synthes

chronOS

β-TCP granules

Wright Medical
Group

Osteoset 3.0 Pellets
MIIG
Pro-Dense

Calcium sulfate
Proprietary alpha crystal technology
Triphasic calcium salt

Zimmer

CopiOs

Calcium phosphate

ceramics, leveraging their osteoconductive nature, nontoxic degradability, compressive
strength and long shelf-life. While variability for clinically-approved materials is limited,
calcium phosphates, calcium sulfates, and hydroxyapatite materials are versatile, soluble
materials that can be combined with ductile polymers and carry mediators. Currently, the
clinically available products are essentially serving as bone fillers; however, transition of
the clinically-approved bone substitutes into bioactive or functional substitute bone
would be easier and quicker than developing novel biomaterials for treating fragility
fractures in diseased bone.
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Table 1.5. Examples of 3D Bone Substitute Construct Designs
Architecture

Macroporous
sponge

Ref.

Pol et al.
2010.

Sintered
Shi et al.
microspheres
2010

Woven fiber

Rapid
prototyped
matrix

Electrospun
fibers

Lee et al.
2011

Wilson et
al.
2011

Li
2006

Material
Composition

βTCP and PL

Fabrication

Characteristics

Supercritical
gas foaming

Macroporous

Construct
Variables

Disadvantages

Undetermined
degradation
Pore size
Undetermined
Mechanical
drug
strength
encapsulation
capacity

High mechanical
Porosity
strength
Mechanical Undetermined
PLG and HA Heat sintering
Controlled
Strength
mechanical
release function
Drug
strength
Macroporous encapsulation

Microporous

Drug
encapsulation

Limited
scaffold
volume
Low
mechanical
strength

Macroporous

Pore size
Organization
Scaffold
volume
Composite
blends

Preliminary
stage of
evaluating
fabrication
technique

Material
Microporous
Silk fibroin
blends
Electrospinning (interconnected)
and HA
Drug
Nanofibrous
encapsulation

Low
mechanical
strength
Limited
scaffold
volume

αTCP and
sodium
alginate

Solution
hardening

βTCP, BCP, Rapid prototype
HA
casting

βTCP = β-tricalcium phosphate, αTCP = α -tricalcium phosphate PL = polylactide, PLG = poly(lactide-coglycolide), HA = hydroxyapatite, BCP = biphasic calcium phosphate

Polymers, on the other hand, are comparatively more versatile than ceramics in
processing, manufacturing, and manipulation, including rapid prototyping,
electrospinning, and in situ hardening of nanofibers, macroporous sponges, and
microspheres (Table 1.5). Natural polymers like chitosan, collagen, and hyaluronic acid
have inherent physicochemical and mechanical properties that can be adjusted through
processing for an intended use [83]. For example, chitosan derived from the exoskeleton
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of crustaceans has intrinsic antibacterial properties, biologically reactive functional
groups, nontoxic degradation, and ductility [83, 84]. There also exist synthetic polymers
such as polylactide (PL), polyglycolide (PG), polyanhydride, and their copolymers that
can be fabricated into varying 3D matrix shapes with sufficient mechanical strength and
controlled degradation [83, 85]. However, the foreign body response to degradation byproducts of orthopedic implants made from synthetic polymers such as polyglycolide and
PL orthopedic implants is non-ideal [86]. To minimize PL or PG bulk mass loss,
scaffolds are fabricated with composite materials incorporating ceramics and polymers.
Composites such as chitosan/calcium phosphate and poly(lactide-co-glycolide)
(PLG)/hydroxyapatite (HA) have been manipulated to mimic bone architecture and
increase biocompatibility [87].
Once a biomaterial or a composite of biomaterials is chosen, the challenge is to
engineer substitute constructs conforming to an array of criteria – architectural
organization, biocompatibility, osteoinductivity, osteoconductivity, biomechanics,
biodegradability, and, most recently, bioactivity – to become biomimetic and functional
as autologous bone. The 3D architectural organization of the material may have
interconnected pores to allow host cell migration, nutrient and waste diffusion, and blood
capillary formation. However, finding a synthetic material with high porosity and
mechanical integrity proves to be a challenging proposition. In addition to overall
architecture, surface micro-topography or roughness can enhance cell attachment and
protein adsorption in bone regeneration. A biomaterial scaffold should be relatively
biocompatible, eliciting no immune response while encouraging cell attachment and
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proliferation. The scaffold matrix should provide an osteoconductive and osteoinductive
environment to recruit progenitor cell attachment, then support and stimulate
differentiation of active bone cells for fracture healing. The scaffold should be absorbed
or remodeled by bone cells and absorbed, remodeling/absorbing at a rate at which
biomechanical stability is sustained and cellular responses stimulated as load is
transmitted.
To advance regenerative medicine, bone substitute constructs have become
biomimetic, bioactive, and functional, serving as drug delivery systems [88]. Current
investigations are focused on mechanisms of loading and solubilizing a biomolecule into
the material itself before scaffold construction, or adsorbing and absorbing the
biomolecule into the scaffold after production. Novel approaches use calcium phosphate
as a drug carrier in electrospun polymers or injectable bone substitutes [55, 74, 76].
In vitro and in vivo assessments are essential to evaluate scaffold properties and
potentials in encapsulating and eluting drugs in a controlled manner to target the
pathology of the particular bone disease. As a review by Baroli suggested,
pharmaceutical scientists focused on bone regeneration will face the challenge of
choosing a specified agent for one particular mechanism in spite of the reality of a
multitude of pathways that orchestrate bone healing reactions [62]. An in vitro test
system can simulate a specific abnormal pathway in the bone disease and allow
consistent characterization of the molecular agent of interest along with fundamental
understanding of the bone substitutes in the pathological conditions. Each molecular
factor, cytokine, and hormone supplement in cell culture medium has been extensively
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studied to obtain the optimal concentration and ratio; however, the effects of cell
concentration and ratio with respect to each other have been of little interest.
Furthermore, the determination of the influence of adipocytes in bone cell regulation has
received inadequate consideration. Some bone diseases are due to the imbalance of cell
ratios and cellular signaling, which can lead to hyperactivity of one and hypoactivity of
the other, resulting in bone malignancies. To simulate in vivo conditions effectively, a
standardized multicellular system should be established to incorporate key cell types,
comparable cell ratios, and molecular controls to allow a coordinated stimulatory
environment for all cell types within an in vitro culture. A multicellular system will allow
efficient characterization and evaluation of the bone scaffold before advancing into in
vivo and clinical testing.
For example, in a case study presented by Eder and coworkers chronOS produced
by Synthes was explanted 28 months after a spinal fusion of a 41 year old female patient
with scoliosis [89]. The explant showed no sign of material resorption and no sign of
bone cell attachment or proliferation. The manufacturer claimed complete resorption of
the β-tri-calcium phosphate within 6-18 months, which was most likely estimated

with no consideration of pathological bone metabolism [89]. With an in vitro
system that can characterize the synthetic material under pathological conditions,
an expedited preliminary screening can estimate potential disadvantages of the
material.
The evolution of bone tissue engineering must include high consideration for
overall patient physiology as well as the objective of fracture management. The process
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of translating scaffold innovations into clinical applications will involve extensive in
vitro and in vivo evaluations to ensure all essential criteria are incorporated –
biodegradability, compressive strength, bioactivity, 3D architecture, manufacturing,
handling, etc. By implementing more requirements for developing functional scaffolds,
investigators will face more constraints in their challenging endeavor for an ideal
regenerative bone substitute.
1.1.8

Constraints in Bone Tissue Engineering
The design of a drug-delivering scaffold to serve as a template for bone formation

and structural support, with the ability to elute biomolecules to mediate normal bone
healing reactions in an abnormal environment, is a challenging endeavor. Systemic
delivery of protective bone agents inhibits bone cell malfunctions and interferes with the
bone’s capacity to repair, while local delivery of growth factors and cytokines stimulates
bone cell remodeling activities at the fracture site. An ideal bone substitute scaffold
would have controlled and sustained drug release, would conserve drug potency and
efficacy, would be low cost, and have a long shelf-life. The encapsulation techniques
should allow predictable control of a biomolecule concentration and of the elution
profile; however, potency and efficacy can be limited by the degradation profile of the
material and the stability of the molecule immobilized in the scaffold. During the
incorporation of the drug into the scaffold, minimal or no conformational changes to the
molecular structure should occur to avoid alterations to drug activity and potency [89].
The production cost of a scaffold should be minimal, allowing ample supply with
no loss in scaffold functionality. The addition of the biomolecule is the limiting factor
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constraining the advances in bioactive scaffolds, especially when dealing with molecular
factors of purified proteins, cytokines, and growth factors. Constraints in potency and
efficacy can be a comparable tradeoff for quantity and quality limitations of autografts
and allografts. Tunability in construct organization and physiochemical properties will
allow specialized substitute scaffolds for different abnormal physiological environments.
1.5

Summary
As commonly taught in biology classes, function follows form; however, in the

case of the body, function follows physiology. Therefore, the fracture management
strategies in pharmaceutical therapy, surgical intervention, and tissue regeneration should
follow the patient’s bone physiology. Patients with bone diseases undergo protective
bone treatments to prevent fragility fractures by inhibiting abnormal cell activity, not by
restoring normal activity. However, when a pathological fracture is sustained, surgical
interventions tend to implement traditional methods of stabilization and fail to account
for compromised bone mechanics. Regenerative bone grafts are commonly used to
provide skeletal continuity for critical size fractures; however, the regenerative capacity
of the graft can be hindered by the protective bone agent. Consequently, it is essential to
integrate all three management strategies to establish a well-rounded treatment that can
mediate bone healing in a diseased bone environment.
Engineering approaches are evolving toward treatment of high risk fragility
fractures in pathological bone with low quality bone fixations and functionalized bone
scaffolds. Hence, function will follow pathology as increased understanding of bone
diseases is applied towards designing disease-specific systemic and local bone
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treatments. Incorporation of bioactive factors should be the norm in the advancement of
engineered fixation devices and bone scaffolds. However, much research is needed to
determine optimal methods and procedures to load and encapsulate the factors without
compromising efficacy. By focusing on regenerative responses in the pathological bone
environments, bone tissue engineering will be able to target the specific abnormality of
the bone disease for the most beneficial and integrated fracture treatment and
management.
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CHAPTER TWO
A CO-CULTURE CHARACTERIZATION OF PRECURSOR CELL RATIO FOR
OSTEOCLAST AND OSTEOBLAST DIFFERENTIATION
2.1

Introduction
Bone is a complex and dynamic tissue with physiological properties and three-

dimensional (3D) organization to maintain bone health and functionality. Bone cells are
constantly communicating with each other to instantaneously respond to physical,
biological, and endocrine stimuli. A signaling cascade causes coordinated cell activity,
leading to renewal and/or repair depending on the specific internal and external mediators
[1-3]. Upon damage due to traumatic injuries or mechanical stress exceeding
physiological healing conditions, therapeutic intervention is required to facilitate good
bone union. Common therapeutic practices are rigid fixation and bone graft implantation,
which provide a mechanically and biologically favorable environment for healing [4-6].
Current clinically available bone grafts are autografts and allografts, i.e. bone tissue
retrieved from the patient or retrieved from donor tissue, respectively [7].
Within the United States, the ≥65 population of baby boomers will exceed 77
million in 2020; this population has the highest prevalence for osteoporosis and fractures
due to low bone mass. Consequently, the demand for bone graft implantation will exceed
the allograft supply, and autograft retrieval can be complicated for older patients [8, 9].
Low biological activity and regenerative capacity of allografts and autografts necessitate
alternate therapeutic options [10-12]. Therefore, bone tissue engineering strategies are
sought to develop bone substitute materials that can induce bone healing with their
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inherent chemical, biological, and mechanical properties [5, 6]. However, ceramic,
polymeric, and composite materials have limited strength, architecture, degradability, and
biocompatibility, as compared to native healthy bone, with respect to facilitating the
healing cascade [11]. Current investigations focus on material enhancements using
regenerative medicine principles of incorporating isolated cells, chemical factors, and
growth factors via adsorption and absorption.
Bone substitute materials bioactivity is limited to mediating bone regeneration
within in the normal bone environment and does not address compromised healing
reactions of diseased bone which is susceptible to non-unions. Advancements in bone
tissue engineering and regenerative medicine must address cellular and metabolic
abnormalities of bone diseases to effectively treat fragility fractures. In order to
characterize the bioactivity of substitute designs, in vitro and in vivo testing systems must
simulate normal and diseased bone physiology.
Transgenic animals have advanced the understanding of the dynamic complexity
of native bone cell coordination and of the differentiation into the osteoclast and
osteoblast lineages [13, 14]. However, in vitro simulation of bone pathology is lacking,
due to the complexities and inconsistencies in current co-culture systems that attempt to
highlight osteoclastic and osteoblastic metabolic coupling. The coordination is
exemplified in the intertwined signaling pathways of hematopoietic and mesenchymal
stem cell differentiation along the osteoclastic and osteoblastic lineage. Secreted
cytokines and factors from either lineage can mediate maturation and activity of the other
[15, 16]. For example, receptor activator of nuclear factor kappa-B ligand (RANK ligand)
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is the key factor produced by osteoblasts to signal osteoclast differentiation through the
RANK pathway, leading to activation of transcription factors [17, 18].
The coordinated partnership is also evident in the bone remodeling cascade, with
a balance in bone resorption and deposition needed to maintain bone health at a defined
ratio of cell concentration and mediators [14, 19]. Any deviation from homeostatic bone
remodeling and balance in cell ratio can result in bone diseases like osteoporosis and
osteopetrosis [20-22]. Histomorphometric evidence of bone biopsies of healthy and
diseased bone exemplifies the morphology and cell ratio differences of osteoclast and
osteoblast cells. For Paget’s disease and bone metastasis from breast carcinoma, the cell
ratios of osteoclast to osteoblast were calculated to be 1:23.1 and 1:1.6, respectively,
while healthy biopsies exhibit a ratio of 1:15 [23, 24]. Consequently, a co-culture
approach to evaluate bone cell response to bone substitute bioactivity is necessary, and
understanding the consistency and relevancy of culture parameters to native bone
metabolism is essential.
The objective of this study was to determine the effect of specific culture
parameters, i.e. precursor cell ratio and differentiation supplement mediator (soluble
RANK ligand), on osteoclast and osteoblast differentiation. Co-culture was conducted,
with three different cell ratios of RAW monocytes and D1 stromal cells under osteogenic
conditions, to monitor differences in lineage maturation. This study also focused on
hematopoietic differentiation in osteogenic and RANK ligand-supplemented conditions
to examine the necessity of the additive in co-culture conditions, where RANK ligand is
secreted by osteoblasts. Gene expression levels of early and late bone cell maturation
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markers were quantified to monitor if in vitro cellular differentiation and activation was
characteristic of that of native bone cells.
2.2
2.2.1

Methods
chronOS Granule Sterilization
To simulate the in vivo environment of bone, chronOS (Synthes) β-tricalcium

phosphate cancellous bone substitute was used as the three-dimensional (3D) matrix for
cell co-culture. The 150mg of granules were placed in scintillation vials (Wheaton)
without caps and sterilized at 200°C under 10 psi, in a vacuum oven (VWR Symphony)
for at least 2 hours. The vials were immediately transferred from the oven to the
Steriguard biological cabinet to be capped with autoclaved vial tops.
Table 2.1. Experimental Setup (n=3)
Cell Ratio (RAW:D1)

Osteogenic (OS)
Medium

1:1= 76000 RAW : 76000 D1
OS1
1:10 = 7600 RAW : 76000 D1
OS2
1:100 = 760 RAW : 76000 D1
OS3
Fluorescence Imaging Samples: OS1, OS2, R1, R2
Controls: growth medium with 1:100 ratio on ChronOS
2.2.2

Osteogenic Medium with
RANK ligand (R)
R1
R2
R3

Cell Culture
Murine RAW 294.7 monocytes (ATTC) and D1 stromal cells (ATCC) were

seeded on chronOS granules in 24-well plates (Corning) with osteogenic medium
(Dulbecco’s Modified Eagle’s Medium (DMEM) (Atlanta Biologics) supplemented with
10% fetal bovine serum (Gibco), 1% penicillin/streptomycin (ATCC), 0.2% fungizone
(Invitrogen), 0.1µM dexamethasone (Sigma), 10mM β-glycerophosphate (Sigma),
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5µg/ml ascorbic acid (Sigma)) supplemented with 30ng/ml RANK ligand (Pepro Tech)
or no supplement. The D1 cells were co-cultured with RAW 294.7 monocytes and
stimulated to differentiate into osteoblasts and osteoclasts, respectively. Each well plate
contained 150mg of chronOS granules; the granules were presoaked in growth medium
for 24 hours at 37°C prior to cell seeding. The experimental layout for the co-culture of
RAW to D1 cell density ratios and experimental groups are shown in Table 2.1. The
culture was maintained for 36 days, samples were collected at Days 8, 15, 22, 29 and 36,
and the medium was changed every other day.
2.2.3

Fluorescence Imaging
Endogenous phosphatases, suggestive of bone cell differentiation, such as

osteoclast characteristic tartrate-resistant acidic phosphatase (TRAP) granules and
osteoblast alkaline phosphatase (ALP) were visualized using fluorescence-based ELF97
staining (ELF97 Endogenous Phosphatase Detection Kit, Molecular Probes). Additional
samples (experimental groups: OS1, OS2, R1, R2) were cultured on four-well chamber
slides (Lab Tek II) for better image quality (Table 2.1). ELF97 staining was performed at
endpoint Day 36 following the manufacturer’s protocol, with two counterstains to reveal
a more defined cellular morphology. Hoechst 33342 (Invitrogen) was used to stain cell
nuclei blue while AlexaFluor 546 Phalloidin (Invitrogen) was used to stain cytoskeleton
actin red, to contrast with the green fluorescence of ELF97. Images were taken using the
microscope (Axiovert 40 CFL, Zeiss) with attached fluorescence lamp under
Hoechst/DAPI and TRITC filter sets.
Ribonucleic Acid (RNA) Isolation
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To analyze gene expression of differentiation markers of cells attached to the
granules, total RNA was isolated at Days 8, 15, 22, 29, and 36 using the TRIzol reagent
(Invitrogen) and protocol. Briefly, medium was removed from well plates before 1 ml
TRIzol reagent was added to lyse cells, then 0.2 ml of chloroform (Honeywell, HPLC
Grade) was added to dissolve RNA into an aqueous phase. The RNA was collected,
precipitated with 0.5 ml isopropyl alcohol (VWR), and washed with 1 ml 75% ethanol
(Sigma). The ethanol was removed and the precipitated RNA was air dried before
resuspending in 30µl of nuclease-free water (Promega). Next, the RNA was treated to
remove any contaminant DNA, using the TURBO DNase-Free kit (Ambion). RNA was
quantified and qualified using a NanoDrop 1000 spectophotometer (Thermo Scientific),
then stored at -80°C until reverse transcription.
2.2.4

Reverse Transcription Real-Time Polymerase Chain Reaction (RT-PCR)
Reverse transcription was performed using the RETROscript kit (Ambion) with

1µg of isolated RNA to synthesize 25 ng/µl of complementary deoxyribonucleic acid
(cDNA). QuantiTect SYBR Green kit (Qiagen) was used to perform real-time PCR with
the primers listed in Table 2.2. Primers were checked for uniqueness with Primer-BLAST
database and efficiency prior to purchase and use, respectively. The StepOne Plus
(Applied Biosytems) was used to run PCR at a holding temperature of 95°C for 15 min,
then 35 cycles of denaturing at 94°C for 15 sec, annealing at 54°C for 20 sec, and
extension at 72°C for 20 sec. Melting occurred at a 70-99°C ramp to check for primer
dimers. The cycle number (Ct) was obtained at a threshold of 0.1 to calculate relative
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expression ratios (RER) of target genes compared to the internal standard, GAPDH, using
the ΔΔCt method as follows:
RER = 2(-ΔΔCt)
ΔΔCt = ΔCt(experimental) –ΔCt(control)
ΔCt(experimental) = Ct(target) – Ct(reference)
ΔCt(control) = Ct(target) – Ct(reference)
Table	
  2.2.	
  RT-‐PCR	
  Primers	
  
Primers	
  

Sequence	
  

Reference	
  

Internal	
  Standard	
  
	
  
	
  

GAPDH	
  

F	
  

5’-‐GAACGGATTTGGCCGTATTG-‐3’	
  	
  

R	
  

5’-‐CGTTGAATTTGCCGTGAGTG-‐3’	
  

[25]	
  

Osteoblast	
  Early	
  Differentiation	
  Marker	
  
	
  
	
  
	
  
	
  

Runx2	
  
ALP	
  

F	
  

5’-‐AGTGGACCCTTCCAGACCAG-‐3’	
  

	
  

R	
  

5’-‐TAATAGCGTGCTGCCATTCG-‐3’	
  

	
  

F	
  

5’-‐GTAACGGGCCTGGCTACAAG-‐3’	
  

	
  

R	
  

5’-‐AAAGACCGCCACGTCTTCTC-‐3’	
  

	
  

Osteoblast	
  Late	
  Differentiation	
  Marker	
  
	
  
	
  

Osteocalcin	
  

F	
  

5’-‐TGCGCTCTGTCTCTCTGACC-‐3’	
  

	
  

R	
  

5’-‐ATGGAAGGCTAAGGGCTCTG-‐3’	
  

	
  

	
  

Osteopontin	
  

F	
  

5’-‐AAAGAGAGCCAGGAGAGTGCC-‐3’	
  

	
  

	
  

	
  

R	
  

5’-‐TGTGGCTGTGAAACTTGTGGC-‐3’	
  

	
  

Osteoclast	
  Multinucleated	
  
	
  
	
  
	
  
	
  

RANK	
  
NFATc1	
  

F	
  

5’-‐GGACGTTCACACTGGTCAGC-‐3’	
  

	
  

R	
  

5’-‐TGCTTCCCTGCTGGATTAGG-‐3’	
  	
  

	
  

F	
  

5’-‐CTCGAAAGACAGCACTGGAGCAT-‐3’	
  	
  

R	
  

5’-‐CGGCTGCCTTCCGTCTCATAG-‐3’	
  

[26]	
  

F	
  

5’-‐CTGCCTTCCAATACGTGCAG-‐3’	
  	
  

	
  

R	
  

5’-‐CCTTTGCCGTGGCGTTATAC-‐3’	
  

	
  

Osteoclast	
  Resorption	
  
	
  
	
  

Cathepsin	
  K	
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2.2.5

Western Blotting
A different study was conducted following a similar protocol to collect protein

lysate for protein production quantification. The difference between the two studies was
the collection time point at Days 7, 14, and 21. Samples were rinsed with phosphate
buffered saline (PBS) (Sigma) twice, before 150µl of Mammalian Protein Extraction
Reagent (M-PER) (Pierce) was added. The samples with M-PER were ultrasonicated
(Sonic Dismembrator, Fisher Scientific) for two 3-second cycles. The lysate was
collected and centrifuged (X-12R, Allegra) for 5 minutes at 14,000rpm, then stored at 4°C until the end of the study. Bicinchoninic acid (BCA) protein assay (Pierce, Thermo
Scientific) was performed to quantify total protein concentration per sample for gel
electrophoresis. Total protein (40µg) was diluted with Laemmli sample buffer (Bio-Rad)
and distilled water, for a total volume of 30µl, and loaded onto 10% Tris-HCl Criterion
gels (Bio-Rad). Proteins on the gel were blotted onto 0.45µm nitrocellulose membranes
(Bio-Rad) for protein detection. Primary antibodies for osteopontin (66kDa) and Runx2
(55kDa) (Rabbit-anti-mouse, Santa Cruz), followed by secondary goat-anti-rabbit
conjugated with horseradish peroxidase (HRP), were used to detect protein at specific
molecular weights. Beta-actin (42kDa) conjugated with HRP (Cell Signaling) was used
as the internal standard. Chemiluminescence imaging was performed using FluorChem™
M (Protein Simple).
2.2.6

Statistical Analysis
The calculated relative expression ratio (RER) average and standard error were

graphed for each target gene. JMP 10 (SAS) was used to perform all statistical analyses
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to detect interaction among the cell ratios, in two differentiation conditions, over time.
Randomized splitplot was implemented to statistically compare gene expression
differences within medium groups (wholeplot) for each cell ratio (subplot) within days. If
significance in the interaction was detected (p<0.05), Tukey-HSD post-hoc analysis
(alpha=0.05) was performed to determine significant effects of the factors. Data averages
were graphed with standard error of mean.
2.3
2.3.1

Results
Endogenous Phosphatase Staining

Figure 2.1. ELF97 endogenous phosphatase images for Day 36 of the study,
for OS and R groups at 1:1 and 1:10 ratios. Blue, red and green fluorescence
indicate nuclei, actin, and phosphatase, respectively. Positive staining for
phosphatase is seen for all samples. Scale bar indicates 50µm.
Fluorescent ELF97 staining images show that phosphatases are present in cell
clusters for both medium conditions of osteogenic and osteogenic supplemented with
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RANK ligand, at cell ratios of 1:1 and 1:10 (ratio 1:100 was not imaged) (Figure 2.1).
However, the images do not reveal morphology that allows distinguishing between the
osteoclast- or osteoblast-like cells. The distribution of fluorescent phosphatases is
sporadic, with no uniformity for all experimental groups.
2.3.2

Real-Time PCR
Osteoblastic differentiation and activity was monitored by the gene expression of

Runx2, ALP, and osteocalcin. Under osteogenic conditions, Runx2 transcription factor
for all the cell ratios demonstrated peak expression at Day 22, followed by lower
expression at Day 29, demonstrating typical cellular differentiation (Figure 2.2A)
(p=0.0002)). However, at Day 36 expression levels were higher than at Day 29.
Statistical interaction of medium condition and cell ratio was not evident for Runx2
expression during the 36 days of culture. Relative expression levels for ALP
demonstrated no statistical influence by medium conditions; however, cell ratios
indicated differences in expression levels (Figure 2.2B) (p<0.0001). Cell ratio 1:100
resulted in significantly higher expression levels as compared to 1:1 and 1:10. OS1 and
R1 expression levels were lowest for all days as compared to the other ratios. Relative
expressions at cell ratio 1:100 (OS3 and R3) were lowest at Day 22 with a rise in
expression for Days 29 and 36 (p=0.0003). For OS1 and OS2, levels were higher at each
time point while R1 and R2 peaked at Day 29. Osteocalcin expression had no statistical
interaction with medium conditions and cell ratio groups (Figure 2.2C). Statistical
analysis indicated no change in expression levels from Day 8 to Day 29, with a higher
expression at Day 36. Osteopontin expression showed no correlation for different
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Figure 2.2. Relative expression ratio osteoblastic and osteoclastic markers
of maturation and activation graphed with standard error of mean. Runx2,
ALP, osteocalcin, and osteopontin are early and late markers for
osteoblastic characteristics. RANK, NFATc1, and cathepsin K are markers
for osteoclastic cells.
medium conditions; however, cell ratio differences were seen, in which OS1 and R1 were
higher than other ratios (Figure 2.2D) (p=0.0457).
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For osteoclastic differentiation and activity expression levels of RANK, cathepsin
K, and NFATc1 were observed. The two different medium conditions resulted in similar
RANK levels; however, there were significant differences between the cell ratios, with
highest expression for the 1:1 group and lowest expression for the 1:100 group
(p<0.0001) (Figure 2.2E). NFATc1 gene expression exhibited differences in medium
conditions (p=0.0041) and cell ratios (p<0.0001) (Figure 2.2F). R medium condition had
a higher expression of NFATc1 than the OS condition. Unlike the RANK expression, the
highest NFATc1 expression was exhibited by OS3 and R3 groups, while the lowest was
seen in the OS1 and R1 groups. The NFATc1 expression levels peaked at 22 days of
differentiation, then decreased by Day 29. Cathepsin K expression, on the other hand,
was different within medium conditions; specifically, high levels were evident for the R
medium condition (Figure 2.2G)(p=0.0041).
2.3.3

Western Blotting
Protein production of osteoblastic Runx2 and osteopontin was observed to

determine differentiation and activation (Figure 2.3). Runx2 production for OS and R
groups was higher from Day 7 to Day 14; however, at Day 21 the R treatment group
decreased in production while OS group in all ratios sustained production. In osteopontin
production, OS ratios increased in production, with Day 21 having the highest while R
ratios demonstrated the high production at Day 7 with lower production on consequent
days.
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Figure 2.3. Western Blot results for Runx2 and osteopontin production during
21 days of co-culture. B-actin at day 7 was used as the internal standard.

2.4

Discussion
Biomaterials synthesized for bone substitute applications are characterized in

vitro to determine cellular response and toxicity of the material in culture with bone cells.
Some groups have co-cultured precursor osteoclasts and osteoblasts to simulate the
paracrine relationship of the bone cells in regulating bone cell differentiation and bone
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healing [19, 27-29]. However, considerations to the cell ratio of the two precursor cells
during differentiation were limited or not mentioned at all.
Osteoclast differentiation depends on the presence of osteoblasts to initiate
paracrine signaling through membrane-bound receptors (RANK) and ligands (RANK
ligand). However, the recruitment of precursor osteoblasts to the site of bone resorption
depends on secreted and membrane-bound factors from osteoclasts. The balance between
bone resorption and deposition is a coordinated effort to maintain bone integrity and
health. Increased bone mass leads to osteopetrosis, while decreased bone density causes
osteoporosis. In healthy bone tissue, histological images reveal that the population ratio
between osteoclasts and osteoblasts is 1:15 or 1:15.5 [23, 24]. Therefore, it is necessary
to determine the physiological bone cell ratio for in vitro culture to simulate the
equilibrium of the bone cells in natural bone tissue in order to establish a co-culture
system optimal for material characterization.
A review of the literature reveals the experimental designs have a bias toward
high osteoclast concentrations in co-culture conditions. This design allows increased
resorption on material surfaces which, in turn, leads to more mineral deposition;
however, the high osteoclast concentration contradicts conditions in native bone. In a
study conducted by Bernhardt and coworkers, human monocytes and human
mesenchymal stem cells in a 25:1 ratio were indirectly co-cultured on collagen tapes for
38 days in RANK ligand-supplemented osteogenic medium. Results showed no
significant difference in TRAP and Cathepsin K expression between the monoculture
control and the indirect co-culture, with very little detection of multinucleated cells via
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scanning electron microscopy [29]. Jones and colleagues, on the other hand, conducted
experiment to compare osteoblast only and osteoclast only culture with co-cultured
osteoclast (primary murine monocytes) to osteoblast (MC3T3-E1) ratio of 100:1. The
cells were seeded on silk fibroin, chitosan films, and poly-l-lactide films to evaluate the
potential of the material to induce bone resorption. Unfortunately, results from TRAP
staining for osteoclast differentiation and material surface roughness for osteoclast
resorption were inconclusive [19]. Using a surface pretreatment approach, Spence and
coworkers stimulated in vitro osteoclast resorption for 21 days, then removed the
osteoclasts before seeding osteoblasts onto the resorbed surfaces of hydroxyapatite and
carbonate-substituted hydroxyapatite discs. Even though the osteoclast to osteoblast cell
ratio was 100:1 in an indirect co-culture, the results indicated increased collagen
synthesis for osteoblasts on the resorbed discs [28]. The Tortelli group investigated 3D
versus 2D co-culture conditions using a 1:1 ratio, under osteogenic conditions, for up to
60 days. Relative gene expressions and histological results revealed that 3D skelite discs
stimulated enhanced osteoblast differentiation, leading to early osteoclastic
differentiation [27]. These studies exemplify the inconsistencies of osteoblast to
osteoclast cell ratio from study to study and that the studies do not mimic the ratios in
native bone tissue; therefore, evaluations of material properties and differentiation
responses are not comparable from laboratory to laboratory and with respect to in vivo
conditions of bone. Consequently, the need for a standard in vitro culture model, with
physiologically-relevant precursor osteoclast to osteoblast ratio, is crucial for a

63

systematic comparison of materials and simulation of coordinated bone resorption and
deposition.
The co-culture of RAW monocytes and D1 stromal cells at three different fixed
ratios under two osteogenic media conditions was evaluated to determine cell ratio and
medium parameters for an in vitro co-culture model. Three RAW:D1 precursor osteoclast
and osteoblast cell ratios, 1:1, 1:10, and 1:100, were chosen with goal of better
mimicking in vivo conditions for clinically relevant evaluations and predictions.
Osteoclast activation and osteoblast activity were observed via fluorescence imaging to
assess multi-nucleation, TRAP granule production, and ALP production. Total RNA was
collected and analyzed for relative gene expression of markers in osteoclast and
osteoblast differentiation.
Positive ELF97 staining for samples in both medium conditions demonstrated the
presence of endogenous phosphatase from either osteoclast TRAP granules and/or
osteoblast ALP. In mono-culture of RAW and D1 cells (data not shown), ALP released in
abundance by D1 cells, while TRAP was limited under osteogenic and growth medium
conditions. Even with actin and nuclei counterstaining, cell clusters could not be
distinguished to examine differences in cell morphology. Hence, ELF97 staining and
counterstaining was not effective for visualizing osteoclast TRAP granules and increased
ALP production due to the release of ALP from undifferentiated cells.
To evaluate osteoblast differentiation, expression levels of Runx2, ALP, and
osteocalcin were measured for stromal cell differentiation and osteoblast mineralization,
respectively, during 36 days in two osteogenic conditions (OS and R) and with three cell
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ratios (1:1, 1:10, 1:100). Runx2 is a transcription factor in the signaling pathway directing
the differentiation of stromal cells into pre-osteoblasts, then into immature osteoblasts;
however, at later stages Runx2 can hinder osteoblast activity [30, 31]. Hence, a high
expression of Runx2 during Day 22 of culture, coupled with a lower expression and the
presence of mature and active osteoblasts at Day 29, indicates differentiation.
Alkaline phosphatase (ALP) expression suggests immature osteoblasts becoming
mature osteoblasts, with increasing ALP levels during maturation and plateaus once
mineralization is initiated. ALP levels for all ratios in both media conditions reached the
highest by Day 29, indicating a maturation and even activation of osteoblast metabolism.
The RANK ligand supplemented medium condition induced does not affect osteoblastic
differentiation according to ALP expression. Cell ratio, on the other hand, does affect
ALP levels, with OS1 and R1 having the lowest expression while OS3 and R3 have the
highest, correlating to the presence of differentiated RAW cells. At closer inspection, the
trough in ALP levels at Day 22 for OS2, OS3, and R3 is unexpected, and possibly
demonstrates the cyclic nature of ALP activity during osteoblast maturation and
activation.
The production of osteocalcin, a calcium-binding protein in osteoblasts, regulates
mineralization and osteoclast activity; hence, expression levels are expected to be highest
during mineralization or at the later time points of co-culture. The expression levels
changed minimally throughout the culture period, with unpredicted peaks on Day 8 for
OS3 and R3. Osteoclast differentiation is initiated, with monocyte clustering and fusion
into multinucleated cells through RANK-RANK ligand signaling. The multinucleated
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cells are then activated and resorb damaged or old bone by secretion of protolytic
enzymes [18, 22, 32]. Osteoclast differentiation from RAW monocytes, monitored
through the expression of membrane receptor RANK, indicates a cell ratio effect. The
pattern of RANK expression is highest at Day 22, with a lowered expression at Day 29
and Day 36 rather than a sustained expression of RANK. The lowering of expression at
Day 29 can be a result of RAW cell fusion or osteoclast apoptosis during osteoclastic
differentiation; hence, a reduction in overall membrane area for the membrane receptor.
The downstream signaling of RANK to RANK ligand was measured by expression of
NFATc1, an early sign of osteoclast differentiation, from Day 8 to Day 22. Hence,
expression of protolytic enzyme cathepsin K was high on Day 15 and Day 22, suggesting
resorption as a late marker of differentiation.
2.5

Conclusions
The evaluation of early and late differentiation precursor osteoclast and osteoblast

markers, with goal of establishing a physiological co-culture model of cell ratio for
precursor bone cell differentiation, demonstrated that high concentration of osteoclastic
RAW cells can suppress early and late osteoblastic D1 differentiation markers.
Furthermore, the results provide histomorphological evidence that osteoclast and
osteoblast population ratio variations can predict healthy and pathological bone
conditions. During osteoclastic differentiation of RAW cells, early markers directly
corresponded with RAW concentration while the late marker was higher with respect to
the RANK ligand condition. Since both osteoclast and osteoblast differentiation and
activation occurred within 22 days of osteogenic co-culture for both medium conditions,
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similar to that seen in other in vitro single and co-cultures, the supplementation for
osteoclastic differentiation in co-culture is nonessential. An in vitro co-culture test system
for coordinated osteoclast and osteoblast differentiation is necessary to consistently
characterize cellular response to materials potential under a healthy or diseased
physiological model. Future studies will focus on confirming precursor cell
differentiation and activation at the 1:10 cell ratio and will focus on validating the in vitro
model for clinical predictions of material failure in pathological bone conditions.
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CHAPTER THREE
MULTICELLULAR CULTURE TO SIMULATE INFLUENCE OF
ADIPOCYTES ON THE OSTEOBLAST AND OSTEOCLAST ACTIVITY IN
VITRO ON 3D BONE GRANULES
3.1

Introduction
Patients with bone diseases have the highest risk of sustaining a fracture and have

high risks of non-unions and mal-unions in fracture healing. Bone diseases are the result
of hyperactive or hypoactive osteoclasts and/or osteoblasts in bone formation and
remodeling, leading to bone fragility. The most commonly diagnosed bone disease is
osteoporosis, with high prevalence in women post-menopause resulting in increased bone
resorption and thinning of cancellous trabeculae [1-3]. The purported cause of
hyperactive osteoclast resorption is increased marrow fat due to aging; hence,
osteoporosis is associated with the obesity of bone [2]. Other bone diseases, such as
osteopetrosis, abnormal bone growth, and osteogenesis imperfecta, lack of collagen in
bone formation, are due to genetic mutations and also lead to bone fragility [4, 5].
Histomorphometric analysis of patient bone tissue biopsy reveals that osteoblast and
osteoclast cellular morphology and concentration vary between healthy and diseased
bone [6-9]. Furthermore, patients with bone diseases undergo bone protective therapy to
retard bone degeneration via inhibition of osteoblastic bone formation or osteoclastic
bone resorption. The drug agents systemically target metabolic pathways with a range of
specificity to bone cells which can further reduce native bone healing reactions within the
pathological environment.
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Current bone fracture management strategies use substitute materials such as
autografts, allografts, and synthetic tissue to fill the bone fracture void for improved bone
healing. The demand for engineered bone tissues will increase in the next decade with
predicted increase of bone fractures due to fragile bone and limited supply of autografts
and allografts [10]. Bone substitute materials are engineered to mimic gold standard
autograft biological and mechanical properties. With limitations in exact mimicry,
engineered substitutes are developed from ceramics, polymers, and their composites to
induce bone healing and bridge the fracture gap. Commercially available bone substitute
materials have limited functionality and insufficient accommodation for the pathological
!Linoleic = !Mineralization

Osteoblast

!Stearic = "Mineralization
!Palmitic = "Mineralization

!PGE2 = !Resorption
!DEX= ! Resorption

Adipocyte

!Leptin= "Resorption
!Adiponectin = "Resorption

Osteoclast

Figure 3.1. Adipogenic regulation of bone formation and resorption through fatty
acid and hormonal secretions.
environment and compromised bone cell activity found in patients with bone diseases.
Advancements to functionalize material constructs include incorporation of bioactive
molecules, cytokines, and cellular components to locally stimulate physiological healing
reaction in healthy and diseased conditions [11-13].
To complement development of targeted bone constructs, evaluations of the
materials should be conducted within similar targeted conditions, diseased or healthy, to
ensure efficacy of construct bioactivity. Hence, in vitro simulation of the bone
environment must also advance to co-cultures of physiological significance, including
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parameters such as osteoclast to osteoblast cell population ratio and indirect effects of
other cell types. The cell population ratio of osteoclast to osteoblast can be determined
with available clinical histomorphometric data of healthy and diseased bone biopsies [8,
9]. Understanding the influence of marrow fat adipocytes on bone cell maturation and
activity can allow mimicry of specific aspects of the disease in vitro [2, 14]. Instead of
understanding only individual effects of fatty acids and adipogenic hormones at various
dosages on bone cell functionality, the inclusion of adipocytes is more relevant to
understanding the synergistic effect of adipogenic regulation of bone metabolism [14-17].
Clinical bone density/mass to fat assessment as well as in vitro studies have shown fatty
acids such as linoleic and stearic can regulate osteoblast mineralization, while adipogenic
hormonal secretions such as dexamethasone and leptin can regulate osteoclastic
resorption (Figure 3.1). Quantification of secreted fatty acids from adipocytes and within
the bone environment has limited precision and reveals no significant differences
between healthy and diseased bone [16, 18, 19].
The purpose of this study was to determine adipocyte influence on co-cultured
differentiation of precursor osteoclasts and osteoblasts by monitoring gene expression
and protein production of differentiation and activation markers. The culture system
included commercially available bone cell-seeded chronOS bone granules in indirect
contact with adipogenic cells. The healthy bone precursor osteoclast and osteoblast ratio
was determined in a in Chapter 2 to be 1:10, respectively; this ratio also correlates to
reported physiological histomorphometric evidence [8, 9]. The goal of this in vitro study
was to determine if the indirect tri-culture system, combining adipocytes with
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differentiating osteoclasts and osteoblasts, demonstrated interactions representative of
diseased conditions without added chemical mediators. That is, the underlying theory was
that cellular mediators secreted from adipocytes, rather than just fatty acid supplements,
would have higher physiological relevance.
3.2

Methods and Materials

3.2.1

Cell culture
The culture system was designed to simulate direct interaction of precursor

osteoclasts and precursor osteoblasts and indirect interaction of the bone cells with
adipocytes, as shown in Figure 3.2. There are several preparation phases to obtain
adipocytes to culture with precursor bone cells summarized in the timeline (Figure 3.3).

Negative Undifferentiated

Control Osteogenic

Tri-Culture Experimental

ChronOS

Adipocyte

D1

Osteoblast

RAW

Control Adipogenic

Osteoclast

Figure 3.2. Tri-culture setup with negative control, positive control, and
experimental group.
To obtain adipogenic cells, D1 cells (200,000 cells per well) (ATCC) were
differentiated in 12-well plates (Corning) for 14 days in adipogenic medium (10ml
growth medium ((DMEM) (Atlanta Biologics) supplemented with 10% fetal bovine
serum (Gibco), 1% penicillin/streptomycin (ATCC), 0.2% fungizone (Invitrogen)) +
250µl human recombinant insulin (4mg/ml)(Gibco), 2µl dexamethasone (1mg/ml
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ethanol)(Sigma), 1ml 5mM 3-isobutyl-1-methylxanthine(Sigma)) prior to tri-culture with
bone cells.
Culture of
RAW:D1
Tri-culture under osteogenic conditions
Differentiation of RAW:D1 to OC:OB

Adipogenic Differentiation of D1s

Day -10

Day -3

Day 0
Tri-culture

Day 4

Day 8

Day 14

Figure 3.3. Timeline for tri-culture, with differentiation phase for adipogenic
cells and initiation of tri-culture
The chronOS granules (~300mg, Synthes) were heat sterilized in disposable
scintillation vials (Wheaton) at 200°C under 10psi in a vacuum oven (VWR Symphony)
for at least 2 hours. The sterile chronOS granules were transferred to Netwells™ (12-well,
75µm mesh, Corning) with 2ml of medium (α-MEM, 10% fetal bovine serum, 1%
penicillin/streptomyocin, 0.2% fungizone) for 2 days. Four days prior to tri-culture, RAW
264.7 monocytes (ATCC) (1.5x105 cells) and stromal D1 cells (1.5x106 cells) were
seeded at a 1:10 ratio, respectively, to allow cell attachment and proliferation.
Differentiation of RAW and D1 cells into osteoclasts and osteoblasts was stimulated with
osteogenic medium (Dulbecco’s Modified Eagle’s Medium (DMEM) (Atlanta
Biologics) supplemented with 10% fetal bovine serum (Gibco), 1%
penicillin/streptomycin (ATCC), 0.2% fungizone (Invitrogen), 0.1µM dexamethasone
(Sigma), 10mM β-glycerophosphate (Sigma), 5µg/ml ascorbic acid (Sigma)). Controls
were differentiated in mono-culture for adipocytes and co-culture for RAW:D1 cells.
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To initiate tri-culture, Netwells were transferred to appropriate well compartments
for the tri-culture experimental, control osteogenic, control adipogenic, and negative
undifferentiated control for 2 weeks of tri-culture (Figure 3.2). Samples (n=3) were
collected at Days 4, 8 and 14 for protein and ribonucleic acid (RNA) extraction to
analyze gene expression of differentiation markers with real-time polymerase chain
reaction (PCR) and protein production via Western Blot. Samples were also collected for
Western Blotting to determine protein production of Runx2, osteopontin, and RANK.
Table 3.1. RT-PCR Primers
Primers
Internal Standard
GAPDH

Sequence

Reference

F

5’-GAACGGATTTGGCCGTATTG-3’

R

5’-CGTTGAATTTGCCGTGAGTG-3’

[20]

Osteoblast Early Differentiation Marker
Runx2

ALP

F

5’-AGTGGACCCTTCCAGACCAG-3’

R

5’-TAATAGCGTGCTGCCATTCG-3’

F

5’-GTAACGGGCCTGGCTACAAG-3’

R

5’-AAAGACCGCCACGTCTTCTC-3’

Osteoblast Late Differentiation Marker
Osteocalcin
Osteopontin

F

5’-TGCGCTCTGTCTCTCTGACC-3’

R

5’-ATGGAAGGCTAAGGGCTCTG-3’

F

5’-AAAGAGAGCCAGGAGAGTGCC-3’

R

5’-TGTGGCTGTGAAACTTGTGGC-3’

Osteoclast Multinucleation
RANK

NFATc1

F

5’-GGACGTTCACACTGGTCAGC-3’

R
F

5’-TGCTTCCCTGCTGGATTAGG-3’
5’-CTCGAAAGACAGCACTGGAGCAT3’

R

5’-CGGCTGCCTTCCGTCTCATAG-3’

Osteoclast Resorption
Cathepsin K

F

5’-CTGCCTTCCAATACGTGCAG-3’

R

5’-CCTTTGCCGTGGCGTTATAC-3’

F

5’- CTCCGTGATGGAAGACCACTC -3’

R

5’- AGCAACCATTGGGTCAGCTC-3’

F

5’- AGCCCAACATGATCATCAGCG -3’

R

5’-TCGAATTCCACGCCCAGTTTG-3’

Adipocyte Marker
PPARγ2

AP2
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[21]

3.2.2

RNA isolation
At Days 5 and 14 of the tri-culture, samples were collected for RNA isolation

using Trizol Reagent (Invitrogen) per manufacturer’s instructions under the 600 PCR
Workstation (AirClean Systems). Briefly, culture medium was aspirated from well plates
before 1ml of TRIzol reagent was added. The well plates with TRIzol were placed on a
plate rocker (VWR Minishaker) for 5 minutes at 200rpm to obtain cell lysates from
within the crevices of the chronOS granules. Lysates were transferred to a 1.5ml RNasefree centrifuge tube (Fisher Scientific) before 0.2ml of chloroform (Honeywell HPLC
grade) was added to
dissolve RNA into the aqueous phase. The aqueous layer was transferred to a new
tube and 0.5ml of isopropyl alcohol (VWR) was added to precipitate the RNA. The RNA
was sequentially washed with 75% ethanol (Sigma). The ethanol was removed, the RNA
was allowed to air dry to remove most of the excess ethanol, then the RNA was dissolved
in 30µl of nuclease-free water (Promega). Removal of DNA contaminants was performed
on the RNA samples using the TURBO DNase-Free kit (Ambion). Quantification and
qualification of the RNA samples were conducted using the NanoDrop 2000
spectrophotometer (Thermo Scientific), then samples were stored at -80°C until reverse
transcription.
3.2.3

Reverse transcription and real time PCR
Reverse transcription with heat denaturation was performed as instructed in the

RETROscript kit (Ambion) with 436µg of RNA samples (amount was limited by RNA
collected). QuantiTect SYBR Green kit (Qiagen) was used to perform real-time PCR
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with primers (Runx2, alkaline phosphatase (ALP), osteocalcin (OCN), osteopontin
(OPN), RANK, cathepsin k (Cap K), and NFATc1) obtained from Integrated DNA
Technologies. The StepOne Plus (Applied Biosystems) was used to maintain a holding
temperature of 95°C for 15 minutes, then to provide 35 denaturation cycles at 94°C for
15 seconds, annealing at 54°C 20 seconds, and extension at 72°C for 20 seconds. Melting
was conducted at a 70-99°C ramp to check for primer-dimers. The cycle number (Ct) was
obtained at a threshold of 0.1 to calculate relative expression ratios (RER) of target genes
compared to the internal standard GAPDH, using the ΔΔCt method.
The RER were analyzed via JMP 10 (SAS) to determine significant mean
differences and interactions (p ≤ 0.05) for osteoclast and osteoblast differentiation
markers at various maturation stages.
3.2.4

Western blotting
To quantify protein production of Runx2 and osteopontin, Western blotting was

performed on isolated protein samples. Protein was isolated using 150µl of Mammalian
Protein Extraction Reagent (MPER; Pierce, Thermo Scientific) per sample using an
ultrasonicator (Sonic Dismembrator, Fisher Scientific) for two 3s cycles. The lysate was
collected and centrifuged for 5 minutes at 14,000rpm, then stored at -4°C. Bicinchoninic
acid (BCA) protein assay (Pierce, Thermo Scientific) was performed to quantify total
protein concentration per sample for gel electrophoresis. Total protein (20µg) was diluted
with 6x Laemmli sample buffer and distilled water for a total volume of 45µl, and loaded
onto 12-well 10% Tris-HCl Criterion gels (Bio-Rad). Proteins on the gel were blotted
onto a 0.45µm nitrocellulose membrane for protein detection. Primary antibodies for
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osteopontin (66kDa) and Runx2 (55kDa) (Rabbit-anti-mouse, Santa Cruz), followed by
secondary goat-anti-rabbit conjugated with horseradish peroxidase, (HRP) were used to
detect protein at specific molecular weights. Beta-actin (42kDa) conjugated with HRP
(Cell Signaling) was used as the internal standard. Chemiluminescence imaging was
performed using a FluorChem™ M (Protein Simple).
3.3

Results

Tri-Culture Osteoblastic Differentiation Markers

6
Day 4

Day 8

Day 14

5

Relative Expression

4

3

2

1

0
Runx2
Control

Runx2
Tri-Culture

ALP
Control

ALP
Tri-Culture

OCN
Control

OCN
Tri-Culture

OPN
Control

OPN
Tri-Culture

Figure 3.4. Osteoblastic gene expression for early and late differentiation markers. No
differences in expression were detected between control and tri-culture group for
Runx2 and ALP. Osteocalcin expression was higher for control group than for triculture group (p=0.428). Osteopontin expression for control and tri-culture groups was
significantly different (p=0.0001)

78

Tri-Culture Osteoclastic Differentiation Markers

7
Day 4

Day 8

Day 14

6

Relative Expression

5

4

3

2

1

0
RANK
Control

RANK
Tri-Culture

NFATc1
Control

NFATc1
Tri-Culture

Cap K
Control

Cap K
Tri-Culture

Figure 3.5. Osteoclastic gene expression of differentiation markers. A correlation
was detected between expression levels and study groups for RANK (p=0.0001) and
cathepsin K (p=0.044). Results show no statistically significant relationship between
downstream transcription factor NFATc1 and study groups.

Gene expression was assessed to monitor differentiation of precursor osteoclastic
RAW cells and precursor osteoblastic D1 stromal cells in indirect contact with
adipocytes. No difference was detected in early-stage osteoblast differentiation genes
when comparing osteogenic control and tri-culture through 14 days (Figure 3.4). No
change was detected in Runx2 levels for either group over 14 days, while ALP
expression peaked at Day 8 for the control group. Significant differences (p=0.0428,
p=0.0001, respectively) were detected in osteocalcin and osteopontin, later markers of
osteoblast mineralization, between osteogenic control and tri-culture groups. The control
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group expressed higher levels of osteocalcin after Day 8. Osteopontin levels in the triculture system increased throughout the 14-day study, while control levels peaked at Day
8.
2.5

PPAR-γ Gene Expression

2

Day 4

Day 8

Day 14

Relative Expression

1.5

1

0.5

0
Control
70

Tri-Culture

AP2 Gene Expression

60

Relative Expression

50

40

Day 4

Day 8

30

20

10

0
Control

Day 14

Figure 3.6. Adipogenic gene
expression of differentiation
markers. Control cultures
expressed higher levels of
PPAR-γ (p=0.004) and AP2
(p=0.0001) as compared to tricultures. Tri-cultures exhibited
a sustained expression of
PPAR-γ while control
expression decreased. Both
conditions showed decreased
AP2 expression throughout 14
days.

Tri-Culture

Lower levels of RANK and cathepsin K, osteoclastic markers, were detected in
tri-culture at Day 8 (p=0.0001; p=0.004) (Figure 3.5). However, the levels of downstream
transcription factor NFATc1 in the control and tri-culture groups were not significantly
different.
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Adipogenic characteristics were monitored through the production of PPAR-γ and
AP2 (Figure 3.6). PPAR-γ expression in the control group decreased after Day 4, while
the level in the tri-culture group plateaued throughout 14 days of the study (p=0.004).
AP2 expression behavior for both groups similarly decreased throughout the study;
however, levels were higher for the control group at Day 4 (p=0.0001) (Figure 3.6).
Protein production of Runx2 and osteopontin, measured by Western Blot,
indicated differences among all groups during the 14-day experiment. Runx2 for the triculture condition was higher than the positive control at Day 4, while minimal production
was evident for the negative control (2D growth). Protein concentration of Runx2

Runx2
Neg

Con

Tri

Osteopontin
Neg
Con

Tri

Figure 3.7. Western Blot for
protein production of Runx2
and osteopontin during14 day
tri-culture (Tri) with positive
(Con) and negative (Neg)
controls. Production of Runx2
and osteopontin are higher in
tri-culture as compared to in
Neg. Tri-culture levels of
Runx2 are greater but the
levels of osteopontin are
similar to those of the positive
control.

Day 4
Day 8
Day 14

Day 4
Day 8
Day 14
B-Actin
(Day 4)
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decreased with time in the osteogenic control and tri-culture conditions, similar to what
one would expect in vivo. Osteopontin production, on the other hand, was produced in
sustained fashion for all 14 days of tri-culture, similar to production patterns in the
positive control. Osteopontin was produced minimally in the negative 2D control as
compared to production in osteogenic conditions.
3.4

Discussion
One hypothesized cause of osteoporosis is the accumulation of marrow fat in

aging, resulting in increased bone resorption and eventually low bone mass [19]. Hence,
women who inherently have higher body fat have higher accumulation of marrow fat
post-menopause and are predisposed to osteoporosis. However, a deeper understanding of
the mechanisms of osteoporosis is necessary to improve preventative measures and
pathological understanding of the condition. Even though clinical evidence from several
studies reveals no significant differences in fatty acids between patients with normal and
osteoporotic bone, researchers are curious about the orchestration between adipogenic
and osteogenic cells [2, 15, 22]. In vitro studies have been designed to understand
lipotoxicity and adipogenic regulation of bone cell metabolism; however, co-cultures
with either osteoblastic or osteoclastic cells on a two-dimensional (2D) environment
exemplify limited understanding of a disease or condition [16, 17, 23, 24]. The inverse
relationship of osteogenesis and adipogenesis can be monitored by the expression of early
and late markers like PPAR-γ and Ap2, respectively. Elbaz and coworkers studied
primary human osteoblasts and osteoclasts in 2D for 21 days and observed lipotoxicity of
stearate and palmitate, resulting in a decrease in osteoblast differentiation and activation
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markers (Runx2, ALP, OCN) [16]. Similar results were observed by Liu and coworkers
in their investigation of PPAR-γ and adiponectin regulation of osteoblastic differentiation
[24]. As for adipogenic regulation of osteoclastogenesis, the Kunh and colleagues and
Hozumi and colleagues confirmed both positive and negative effects on differentiation
and activity with direct and indirect cultures [17, 24].
Studies in the literature have suggested the inverse relationship between
adipogenesis and osteogenesis as a hypothesis for osteoporosis pathogenesis. However,
as demonstrated clinically, cell population ratios also influence cellular activity [8, 9].
Indeed, the indirect tri-culture with adipogenic cells demonstrated influence of fat on
osteoblast activation and osteoclastogenesis. Statistical analysis revealed no differences
in osteoblast expression of transcription factor Runx2 or ALP, indicators differentiation.
However, Runx2 production measured via Western Blot was higher in tri-culture
conditions; it is known that mineralization of osteoblasts can be hindered due to
excessive Runx2 signaling [25]. Osteocalcin and osteopontin expressions were higher in
the control groups, suggesting suppressed osteoblastic activity in the tri-cultures. On the
contrary, no difference was seen between osteopontin production in the control group and
that in the tri-culture group. Osteoclast maturation and activation, confirmed via RANK
and Cathepsin K levels, were also retarded by adipogenic presence during the 14-day
culture period. Interestingly, the decrease in PPAR-γ evident in the control conditions is
phenotypic once stromal cells commit to adipogenic lineage, while sustained levels
PPAR-γ exhibited in the tri-culture condition suggested indirect regulation of adipogenic
maturation by soluble factors from co-cultured osteoclastic and osteoblastic cells.
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Expression difference of AP2 further supports the theory that communication within the
tri-culture condition is bi-directional.
3.5

Conclusion
Soluble cytokines and factors produced by adipocytes, osteoblasts, and osteoclasts

orchestrate the differentiation and activation within a tri-culture condition. Adipocytes
suppress both late osteoblast maturation and mineralization and down-regulate osteoclast
differentiation and resorption activity. Adipogenic activity is altered in tri-culture
conditions as compared to mono-culture conditions. Recognizing the complex
communication pathways between adipocytes, osteoblasts, and osteoclasts, an in vitro
test system with clinical relevance can be established to model osteoporosis and
characterize bone substitute materials for patients with bone diseases. By further altering
the adipocyte:osteoblast:osteoclast cell ratio, a deeper understanding of pathological-like
activity can be realized and used to evaluate the effectiveness of bone substitute materials
in targeting fragility fractures.
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CHAPTER FOUR
A LOOK AT BIOMEDICAL ENGINEERING PRINCIPLES AND MEDICAL
DEVICES THROUGH BONE DISEASES AND BONE IMPLANTS
4.1

Introduction
Within biomedical engineering (BME), there are multiple concentrations/foci

requiring a variety of engineering and science expertise and collaboration. Medical
device technologies developed by biomedical engineers range from imaging machines (xray, magnetic resonance) to diabetic monitors to pacemakers to bandages. The focus of
this teaching module is on bone tissue engineering, in which engineers/scientists
strategize to resolve complications in bone healing, bone fractures, and bone diseases
with medicinal agents, medical devices, and engineered tissue or substitute materials.
Hence, bone tissue engineering is an interdisciplinary field of biology, anatomy and
physiology, chemistry, mechanical engineering, physics, and material science. The
introduction of BME through implementation of this bone fracture education module will
demonstrate to the students the core ideas of engineering design and practices according
to the Next Generation Science Standards (NGSS). The education module distills BME
concepts, with focus on bone tissue engineering, into a 1-hour demonstration with a
hands-on activity of simulated bone and bone implants that is easily translated to a
classroom setting for all grade levels. The presentation introducing BME, bone biology,
and the activity can be downloaded from DropBox
(www.dropbox.com/s/uwk7qfpzzed5khb/Biomedical%20Engineering%20Workshop.ppt
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x) and can be tailored for a specific grade level according to NGSS performance
expectations.
Bone implant design is a relatable example as children are at risk for bone
fractures, leading to casting for simple fractures and bone implants and surgery for
complex fractures. Depending on the location of the complex fracture, bone implants can
be a system of screws and plates (long bones), intramedullary nails (long bones), rods and
screws (spine), and joint replacements (knees and hips). Bone implants are devices used
to mend two pieces of bone, and are similar to hardware supplies used to build a house.
Plates and nails/screws are used to join to planks of wood in fixed fashion, while hinges
and screws are used in joints on doors to allow movement. The material, size, and shape
of the plates, screws, and hinges depend on such factors as the type of wood, the load the
house frame needs to support, the forces that the house frame will encounter. Similarly,
factors such as age, health, and gender will influence implant selection for a patient.
Many implants are designed to be removed following bone healing. For example, if a
child receives an implant, such as screws and plates, to mend a complex fracture in the
humerus, the screws and plates will likely be removed once the fracture is healed to allow
further bone growth and avoid bone deformity.
The module will allow students to experience the process of implant development
– designing, testing, redesigning – and determine necessary features for a successful bone
implant system to accommodate the clinical need, patient specifications, and surgical
feasibility. The long bone fracture is simulated using cardboard tubes as cortical bone for
shape similarity and accessibility while the styrofoam and foam insulation represents
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cancellous/spongy bone (Figure 4.1). As the students learn about BME, they should also
understand that medical device design means balancing requirements in various criteria:
•

•

•

Biology Criteria
o Supports the body and/or body functions
o Causes minimal to no immune response
o Causes no further damage
Patient Criteria
o Accommodates all sizes and shapes
o Allows quick recovery
o Promotes good healing
o Minimizes costs after insurance
Surgeon Criteria
o Facilitates minimal surgical trauma
o Accommodates short implantation time
o Comprises minimal parts or pieces
o Has low chance of failure
In house construction, the location (geographic region, immediate surroundings),

the budget, and the potential homebuyer preferences determine the type of material, the
architecture, and the foundation. That is, the home should withstand weather conditions,
be aesthetically pleasing, and be accommodating.
Even though an engineer can have the best design to address the biology criteria,
if the implant does not meet the surgeon’s criteria, then it is a failure. The process of
commercializing an implant takes years due to testing, retesting, and approval
procedures. An engineer designing a biomedical product, such as a bone implant, must
wear a variety of thinking caps in order to meet the demands of the customers (the
patients and surgeons). Therefore, during the hands-on activity or the engineering
challenge, inquiry questions (Table 4.1) stimulate students to seek different answers
depending on the cap they are wearing. Follow-up questions are asked that lead the
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students to think about compromises and compare the importance of one criterion against
the other.
4.2

Understanding Bone Function and Physiology
The 206 bones in the adult skeleton provide protection for the internal organs,

support to keep the body upright, and movement at joints. Without the skeleton, the body
would be floppy skin, organs, and muscles, found in a pile on the ground, unable to
withstand gravity. The architecture of bone is a complex network of trabeculae, even
more advanced and geometrically efficient than the scaffolding of the tallest skyscraper.
The synergistic combination of inorganic (hydroxyapatite) and organic (collagen)
components gives bone high compressive and tensile strength, respectively. Cortical, or
compact, bone has higher compressive strength than cancellous, or spongy, bone; hence,
cortical bone is arranged on the exterior of the bone while cancellous bone is on the
interior. The spongy interior of long bone serves as a storage and source for bone marrow
rich in essential red and white blood cells.
Bone has the unique ability to heal minor bone defects without leaving a scar; that
is, bone continuously remodels and repairs small unnoticeable damages a person might
sustain. Unfortunately, bone diseases and complex fractures do occur, leading to
compromised or no healing. One of the most common bone diseases worldwide is
osteoporosis, or low bone mass, which decreases the mechanical strength of bone. Since
many patients with bone diseases develop brittle bone, they have the highest risk for
fractures. Biomedical engineers have been designing and redesigning bone implants to
resolve this problem.
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When a person breaks a bone, the doctor evaluates the fracture to categorize it to
ensure the best treatment for good bone healing. The preferred treatment would be a
simple external cast made of plaster, but for patients with complex fractures, internal
fixation with implants is necessary to realign the bone. For patients with bone diseases,
such as osteoporosis, the brittle bone can be damaged with the implantation of a screw or
other implants, leading to a fracture. Some engineers have recognized this design
problem and are focused on balancing the biological and mechanical criteria for bone
implants. Commercially available plate and screw options include titanium, stainless
steel, and cobalt alloys; the selected system must allow mechanical strength to support
body weight while the fracture heals. Clinically, a plate is implanted to hold the fractured
bone in place; screws are placed some distance away from the fracture gap, at varying
angles, to stabilize the plate.
During design and development of bone implants, engineers brainstorm to
consider implant material, chemistry, implant shape, implant mechanical and biological
properties (compressive strength, manufacturability, biocompatibility), clinical
application, ease of implantation, and fracture site. Once a product design is
conceptualized, a prototype is produced for testing to optimize implant properties and
eliminate possible failures. If the design survives testing and the clinical approval
process, the time from concept design to commercialization is years. This hands-on
activity allows students to implant plates and screws using a simulated fracture of normal
and osteoporotic bone and demonstrates the engineering design process, from prototype
to testing to redesigning, for bone with biological and mechanical differences.
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4.3

Education Module Implemented at Girl Scout Event 2013
A BME education module was developed to implement at a 1-day event that

focused on introducing various engineering and science fields to a group of ~50 girl
scouts (6th – 8th grade) from the Upstate region of South Carolina. The BME module was
one of three science or engineering modules, each geared toward hands-on and
interactive teaching. Before the demonstrations started, the girls were split into three
groups to rotate through each module during the day.
Table 4.1 Questions Focused on Engineering Practices
Interactive Presentation
What is biomedical engineering?
What are the functions of bone?
What bone are the two types of bone?
Who has had a broken bone?
How does broken bone heal? Is it different for children and adults?
What are the problems of bone disease?
How was your bone stabilized to heal?
What are the differences and similarities of this broken bone model to real broken bone?
What are the limitations of the model?
Are the materials used a good representation of bone?
What part of the bone does the cardboard/styrofoam represent?
Why is metal the material of choice for bone implants?
Hands-on Activity
What material would you use? Plastic or metal?
How many plates/screws would you use?
Where would you put the plates/screws?
Think like an
What material would you use for the osteoporosis fracture? Why?
engineer
If the implant can fail, how do you think it will fail?
How can you calculate the forces in the mechanical testing?
If you were performing this surgery on a real person, how could you
limit the surgery time?
How many implants would you use?
Think like a
How many screws would you use?
surgeon
Does the implant need to be clean before it is implanted?

For each group of girls, the bone implant demonstration started with a
presentation to introduce BME, bone biology, bone mechanics, bone health, and fracture
treatments. The presentation was interactive; the girls were encouraged to respond to
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questions listed in Table 4.1 during the appropriate times. The girls were asked if they
had ever broken a bone or if they knew anyone who had; they were then asked how that
fracture was treated and if there were complications with healing. The presentation then

Figure 4.2. Components of the bone implant kit for two
students: fake bone, screws, plastic plates, and metal plates.

transitioned into methods of treating bone fractures, with details on bone implant devices
and designs. During the implant design discussion, the girls were asked what
characteristics and considerations would benefit a bone implant. Once they had defined
the problem and brainstormed some design criteria, a humerus fracture was introduced as
the engineering challenge. The girls were given the activity kit and the tools to start their
implantation, which included two models of bone fractures (normal and osteoporotic,
Figure 4.1). The girls observed the differences in the color and the hardness of the two
broken bone models. To stimulate their engineering thinking, the girls were asked what
material they would use as an implant for the normal and osteoporotic bone (Figure 4.2).
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After the girls finished their implant (Figure 4.3), they performed bend, torsion, tension,
and compression tests to observe the changes and failures with their designs (Figure 4).
Testing was the best part for the girls since they were allowed to attempt to break what
they just designed and fixed.
For the bend test, the girls oriented their fixed bone model horizontally and bend
the model holding the two bone segments. For the torsion test, the girls twisted the two

Figure 4.3. Example of fracture repair of
simulated bone fracture with ~1 inch gap for testing.
bone segments in different directions. For the tension test, the girls pulled their two bone
segments apart. Lastly, for the compression test, the girls placed their bone models on
end on the ground, placed a large cardboard tube (2 feet tall) around the model, and
dropped dumbbell weights (3, 5, and 8 pound weights) down the tube, on top of the bone
model, to test how much load their plate and screw setup could support. Groups that
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finished first had time to redesign and retest their implant systems. The girls had an
opportunity at the end of the session to summarize their findings to the rest of the class
and suggest improvements to their design for both the normal bone and osteoporotic
bone. The girls were able to take their bone implants home to remind them about
biomedical engineering.
To gauge the girls’ attitudes towards math, science, and engineering, before and
after the events of the day, survey questions were posed targeting the girls’ interest in,
value of, and confidence toward the three fields. The questions followed the Likert Scale,
with a 5-point rating scale ranging from 1 as “strongly disagree” to 5 as “strongly agree”.
Pre- and post-surveys with similar questions were given to students at the beginning and
end of the day, respectively, to measure changes in the students attitudes towards math,
science, and engineering. The survey data showed that the interest, perceived value, and
self-confidence with respect to science and engineering statistically increased over the
course of the 1-day event.
4.4

Attitude Survey Assessment
To gauge the girls’ attitudes towards math, science, and engineering, before and

after the events of the day, survey questions were posed targeting the girls’ interest,
value, and confidence of the three fields. Questions for the survey were revised from
those published by Gibbons and colleagues to measure middle school students’ attitude
and knowledge about engineering [1]. The questions followed the Likert Scale, with a 5point rating scale ranging from 1 as “strongly disagree” to 5 as “strongly agree”. Pre- and
post-surveys with similar questions were given to students at the beginning and end of the
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Table 4.2 Pre- and Post- Survey Results for Girls Scout Event
Category
Question
n
p-value
I like math
33
Interest
I like science
33
0.0325
I like engineering
33
0.0005
It is important for me to learn math
33
Task Value
It is important for me to learn science
32
0.0181
It is important for me to learn engineering
33
0.0041
I am good at math
33
I am good at science
33
I am good at engineering
33
0.0044
Confidence
I can be a mathematician
32
I can be a scientist
33
I can be an engineer
33
Mathematicians help people
32
Expected
Scientists help people
33
Outcomes
Engineers help people
33
Values indicate significant positive change (Pre-Post)
Table 4.3 Pre- and Post- Survey Results for STEM Day Event
I am interested in math
I am interested in science
I am interested in engineering
Interest
I want to learn more math in college
I want to learn more science in college
I want to learn more engineering in college
Math will be important for my future
Task Value
Science will be important for my future
Engineering will be important for my future
I am good at math
I am good at science
I am good at engineering
Confidence
I have the skills to be a mathematician
I have the skills to be a scientist
I have the skills to be an engineer
Mathematicians help solve society's problems
Expected
Scientists help solve society's problems
Outcomes
Engineers help solve society's problems
Values indicate significant positive change (Pre-Post)

p=0.0005

p=0.002

p=0.0005

p=0.0027
p=0.0039
p=0.0156
p=0.0191

day, respectively, to measure changes in the students attitudes towards math, science, and
engineering. Data distribution was expected to be skewed and nonparametric; hence, the
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Wilcoxon Signed Rank test nonparametric data analysis for matched pair changes was
employed for each question using statistical software JMP 10 (Table 4.2 and 4.3). Total
sample size was n=45; however, the usable sample number was reduced to n=33 or 32
due to missing “pre” or “post” survey answers for the Girl Scouts and n=24 for the
juniors. The survey data showed that the interest, perceived value, and self-confidence
with respect to science and engineering increased over the course of the 1-day event.
Furthermore, the positive attitude changes for juniors in high school during this science,
technology, engineering, and mathematics (STEM) awareness, 1-day event indicates an
immediate impact on students of varying grade levels.
4.5

Materials and Assembly
Supplies per student will cost ~$5 for 80 or more students. Preparation and

assembly are required prior to activity (Table 4.4). To make the simulated normal bone,
Table 4.4 Materials List and Feasible Substitutes
Specifications
Supplier
Light-Duty Paper Tubes, 2”x20”,
Paper cylindrical tubes
www.yazoomills.com
0.0045” thick - 23612
Styrofoam poles
Extruded Styrofoam poles, 2”x36”
www.thecraftplace.com
Great Stuff™ insulating
Insulating foam sealant- gaps, cracks
Lowes
foam
Metal mending plates
The Hillman Group 0.5” x 4.5” x0.35”
Lowes
Special made with laser
Plastic mending plates*
Similar to metal plates
cutter
The Hillman Group, 100 count 8x 3/4
Screws
Lowes
zinc plated metal screw
Equipment
Substitutes
Purpose
Cut tubes into fragment
Band saw
Hand held saw
sections
Hollow out center of
Drill press
Apple corer and hammer
foam
Phillips screw driver
Tighten screws
Nail
Push pin
Make hole for screws
Weights – 2,5,8 lb
Heavy books
Test the implants
*Substitutes: plastic screws, different metal plates, different thickness metal plates, or none
Materials
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insert the styrofoam pole into the cylindrical tube and cut into 2” segments, then hollow
out a 1” diameter hole in the center. The osteoporotic bone segment is made by spraying
insulation foam into the tube and allowing the foam to cure overnight. Once the foam has
set, hollow out the center like the normal bone (Figure 4.1). Assemble the kits with the
components as shown in Figure 4.2, targeting two students per kit.
The list of materials includes the basic suggestions that can be expanded upon to
challenge the students or make the activity more specific to the classroom. Variation in
the plates and screws would address the engineering process more as the students interact
with common materials in uncommon conditions (Table 4.4).
4.6

Hands-On Activity Setup
After present the background on the activity, the students had an opportunity to

look at their activity kit to discuss and assess their plan of construction. In groups of two,
the students will choose and help each other to either repair the normal or osteoporotic
fracture. Once the fracture has been repaired (Figure 4.3), students will make
observations and predictions about their implant properties then conduct mechanical tests
(Figure 4.4). The students will perform a bend, torsion, tension, and compression test
with a one-inch gap between the two bone segments, similar to actual test setup and
testing conducted on actual plate and screw bone implant system. The compression
testing will be the most destructive test, with the heaviest weight causing implant failure.
After testing, students will record what they observed through testing, noting the possible
improvements to decrease implant failure.
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Figure 4.4. Schematic of the bend, torsion, tensile,
and compression tests for the bone implant.
4.7

Teaching Assessment
The education module and activity will allow teachers to implement the eight

practices of engineering and practices from the Framework for K-12 Science Education:
Practices, Crosscutting Concepts, and Core Ideas (2012) by the National Research
Council. Teachers can stimulate questions (Table 4.1) as they present the module and the
activity. As the bone fracture scenario is presented to the students, they can practice their
writing in defining the medical problem and devising solutions. They can do so
individually then discuss with their partner for different ideas and share their
interpretation of the bone model. Even though the plates and screws are provided, both
teachers and students can still be creative in the materials and implementation as
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summarized in Table 4.5. For example, if students are given two plates, some will decide
to use one and other decide to use two. However, with two plates students can stack them
together to increase the thickness and possible the mechanical strength or place the plates
with distance apart. Typically students will want to drill the screws straight into the bone
model but they can also try to angle the screws for stability at various angles. Students
are also challenged to think differently for the osteoporotic bone versus the normal bone
in consideration for the change in bone mechanical properties.
Table 4.5 Variations in Fracture Fixation
Plates

Screws

Materials

Angle

Angle

Metal

Displacement (if
more than one)

Displacement

Plastic

Length

Length

Wood

Quantity

Quantity

Thickness

Threading

Width

Diameter

The questions, listed on Table 4.1, can be modified to become assessment or
evaluation questions that can focus on one particular subject area within the
multidisciplinary field of BME. For example, in a biology class, teachers can expand
upon the components of bone, the growth of bone, the healing reaction of bone, the
functions of bone, compatibility of materials to the body. For a physics class, the teachers
can focus on the mechanics (forces, stresses, momentum, etc.) of bone from the microscale of trabeculae in long bone to macro-scale of the bone and joints in abduction and
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adduction. In a chemistry class, students can learn about material science of metals, bone
matrix composition, and the sterilization procedure of implants.
Before students begin the activity they can assess the materials they have and plan
out their initial design. Students can then write down their predictions, observations, and
results from the mechanical testing to evaluate for the redesigning of the plates and
screws to increase the mechanical stability of the implant system for both the normal and
osteoporotic bone model. Observations of implant failure during the mechanical can be
quantitative for math-based classes or qualitative for biological classes. Calculations of
load on bone for various body types and locations in the body and forces from the
compression testing to understand the restrictions of the design and improve on the
redesign. Students can then evaluate the data and observations to explain why the implant
was failing to reassess their model and alter their design with different ideas. At the end
of the module, students can present their findings, complications, and successes to the
rest of the class. At the end, the students should relate to the boarder impact of
engineering design and problem solving to help society such as biomedical engineering in
solving health problems through advanced medical devices.
4.8

Modifications to Meet Education Standards Specific to Grade Groups
This teaching module can more details on bone implants, bone physiology, and

bone diseases in accordance to the Disciplinary Core Ideas of Progression to increase the
sophistication of student critical thinking (Table 4.6). Teachers can incorporate all or
some of the suggestions in the presentation provided to relate to their class syllabus.
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Table	
  4.6	
  Tailoring	
  the	
  Presentation	
  and	
  Activity	
  to	
  Incorporate	
  Core	
  Ideas	
  
	
  

K	
  –	
  2th	
  Grade	
  
Physical	
  
differences	
  in	
  
plastic,	
  metal,	
  
and	
  bone	
  

Physical	
  Science	
  

Different	
  forces	
  
bones	
  can	
  handle	
  

	
  

3th	
  –	
  5th	
  Grade	
  
Mechanical	
  
differences	
  in	
  
plastic,	
  metal,	
  
and	
  bone	
  
Types	
  of	
  forces	
  
that	
  cause	
  
different	
  bone	
  
fractures	
  

6th	
  –	
  8th	
  Grade	
  
Atomic	
  structure	
  of	
  plastic	
  
and	
  metal	
  plates	
  and	
  
screws	
  
Stability	
  of	
  the	
  implant	
  
system	
  with	
  different	
  plate	
  
and	
  screw	
  lengths	
  and	
  
displacement	
  	
  
Transfer	
  of	
  body	
  weight	
  
onto	
  the	
  implant	
  

	
  

Science	
  in	
  Personal	
  
and	
  Social	
  
Perspectives	
  

Science	
  and	
  Technology	
  

Life	
  Science	
  

	
  

Functions	
  of	
  arms	
  
and	
  legs	
  
Importance	
  of	
  
bone,	
  muscle,	
  
tendon	
  
Introduction	
  of	
  
medical	
  devices:	
  
bone	
  implants	
  	
  
Treatment	
  
methods	
  for	
  bone	
  
fractures	
  
Importance	
  of	
  
implant	
  to	
  help	
  
bone	
  heal	
  

	
  

Function	
  of	
  the	
  
skeletal	
  system	
  
and	
  interconnect	
  
systems	
  (muscles,	
  
tendon)	
  
Growth	
  of	
  body	
  
with	
  a	
  focus	
  on	
  
bone	
  
Difference	
  
between	
  bone	
  
and	
  bone	
  implant	
  	
  
Biological	
  design	
  
criteria	
  of	
  bone	
  
implant	
  

9th	
  –	
  12th	
  Grade	
  
Mechanical	
  properties	
  due	
  to	
  
atomic	
  structure	
  of	
  different	
  
plastics	
  and	
  metals	
  
Defect	
  propagation	
  of	
  plastics,	
  
metals,	
  and	
  bone	
  to	
  cause	
  
failure	
  
Chemical	
  properties	
  of	
  metal	
  
and	
  plastic	
  
Erosion	
  of	
  metals	
  in	
  the	
  body	
  
due	
  to	
  micro-‐motion	
  
Forces	
  (stress	
  and	
  strain)	
  
transmitted	
  to	
  plates	
  and	
  
screws	
  
Potential	
  and	
  kinetic	
  energy	
  
supported	
  by	
  the	
  implant	
  
Motion,	
  energy,	
  and	
  forces	
  in	
  
movement	
  of	
  the	
  skeleton	
  or	
  
extremities	
  	
  

Structure	
  and	
  composition	
  
of	
  bone	
  (organic,	
  inorganic	
  
minerals,	
  cells)	
  

Function	
  of	
  bone	
  cells	
  in	
  
maintaining	
  bone	
  health	
  and	
  
healing	
  bone	
  fractures	
  

Functions	
  of	
  bone	
  

Causes	
  of	
  bone	
  diseases	
  due	
  
to	
  malfunctioning	
  feedback	
  
systems	
  

Function	
  of	
  bone	
  implant	
  
in	
  healing	
  

Examples	
  of	
  various	
  bone	
  
implants	
  differing	
  in	
  design	
  

Clinical	
  criteria	
  for	
  bone	
  
implants	
  

Examples	
  of	
  biomedical	
  
technologies	
  used	
  to	
  better	
  
quality	
  of	
  life	
  for	
  the	
  users	
  

	
  

Importance	
  of	
  biomedical	
  
engineering	
  technology	
  in	
  
healthcare	
  

	
  

Importance	
  of	
  
bone	
  health	
  

Development	
  of	
  healthy	
  
bone	
  

Aging	
  of	
  bone	
  	
  

Aging	
  of	
  bone	
  

Diseases	
  of	
  bone	
  

Diseases	
  of	
  bone	
  
Treatments	
  for	
  bone	
  
diseases	
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Bone	
  diseases	
  in	
  older	
  
population	
  and	
  female	
  
population	
  
Treatments	
  for	
  bone	
  diseases	
  
	
  

4.9
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CHAPTER FIVE
CONCLUSION
The advancement of tissue engineering and regenerative medicine will rely on the
development of bioactive tissue substitutes with specificity for diseases and effectiveness
in pathological conditions. In bone tissue engineering, strategies are focused on localized
delivery of bone protective agents via bone substitute biomaterials; surface coatings on
internal implants improve integration and reduce osteolysis. To predict clinical outcome
of these innovative designs, devices and matrices must undergo sophisticated in vivo and
clinical testing. However, the fundamental in vitro testing system can also be as
sophisticated with elevated mimicry of the physiological and pathological bone
environment. Establishing in vitro culture systems focused on standard parameters of cell
population ratio, seeding order, and soluble mediators for native bone metabolism will
allow for screening of the effectiveness of tissue engineered designs. Various
investigations to characterize bioactivity of bone substitute constructs have used monoand co-cultures; however, culture parameters such as cell population ratio and
differentiation supplements are unconsidered and inconsistent. The objective of the
proposed work is to establish the parameters for cell ratio determination, using RAW
monocytes and D1 stromal cells and osteogenic conditions, with or without RANK ligand
supplements to induce osteoclastogenesis. Specifically the objective was to pinpoint
those cultures that demonstrate phenotypic gene expression during differentiation
towards osteoclasts and osteoblasts on a 3D bone substitute material. To further simulate
the natural bone environment, the co-culture parameters in a tri-culture system allowed
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the evaluation of the paracrine effect of adipocytes on osteoclast catabolic and osteoblast
anabolic metabolism in remodeling.
The first two aims of the project focused on evaluating osteoblastic and
osteoclastic differentiation, with varying cell population ratio, on a 3D bone environment
to emphasize the balance in bone metabolism. Furthermore, the influence of RANK
ligand on induction of osteoclast differentiation was assessed. Gene expression indicated
cell ratio as a variable in regulating osteoblastic mineralization with no effect on
maturation while regulating osteoclastogenesis with no effect on activation of osteoclasts.
The coordination of osteoclastic and osteoblastic differentiation and activation at the 1:10
ratio is comparable to clinical observations derived from normal bone biopsy
histomorphometry. As for RANK ligand addition to induce osteoclast differentiation and
maturation, the relationship was not statistically significant in co-culture with precursor
osteoblasts, the native producer of RANK ligand. In addition, Western blot results
indicate that the addition of RANK ligand hinders production of differentiating and
mineralizing proteins in osteoblasts. Hence, the use of RANK ligand should be avoided
to minimize inhibition of osteoblastic activity. Within a co-culture system of precursor
osteoclasts and osteoblasts, the cell population ratio needs careful consideration in order
to appropriately mimic relevant aspects of physiological and pathological conditions.
The chance of the reported clinical failure of chronOS in treating a patient with
scoliosis could have been significantly reduced by screening for bioactivity using a coculture in vitro system with a 1:1 osteoclast to osteoblast ratio. The use of normal
progenitor cells at an abnormal ratio would simulate scoliosis with normal bone
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conditions, an imbalance in bone catabolism, and anabolism during spinal development.
At the 1:1 test system ratio, early osteoblastic differentiation was lower on chronOS
while early osteoclastic differentiation was higher. Minimal osteoblastic migration and
abnormal osteoclastic multinucleation can lead to no bone formation or resorption, as
seen on the explant.
To understand the regulatory influence of adipocytes on the differentiation of
bone cells, a tri-culture system was designed to allow indirect co-culture of bone cells
with adipocytes. Results indicated that the presence of adipocytes hindered osteoclastic
maturation and activity while only affecting the mineral deposition of osteoblastic cells
and not the early maturation. The tri-culture system can be applied as an osteoporotic test
system or can be applied to other disease environments, with variations in cell ratio and
cell types. The characterization of bone constructs in advanced in vitro test systems at the
early stage of development can facilitate the inexpensive prediction of biological failures
before in vivo testing. Hence, developing the tri-culture system to be more clinically
relevant will improve the ability to predict bone construct bioactivity in an in vivo
environment.
For diseases in which bone cell activity is abnormal, further considerations are
necessary. The in vitro systems can become complex with four or more cell types and
even inclusion of inflammation conditions; however, in vitro test system design should be
simple and yet mimetic to provide a quick pass/fail preliminary screen that leads to
continued in vivo testing or to selection of a new material.
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The fourth aim of this research project focused on introducing biomedical
engineering to middle and high school students with a teaching module about bone
implants, bone biology, and engineering design. The teaching module was implemented
at a Girl Scout event for middle school girls and a Science, Technology, Engineering and
Mathematics event for high school juniors. Students were encouraged to be curious and
creative during the presentation and hands-on activity, as the differences and importance
in bone health regarding the simulated bone fracture were presented. They also learned
about the differences in fracture management in which implants are the last resort. In
their design of the implants, students gained understanding of the difficulty of implanting
the bone screws and plates on even the simulated bone. During the testing of their fixed
fracture, the students were reminded that the most important part of engineering design is
to avoid implant failure for patients. Survey results demonstrated that the teaching
modules with the incorporated bone implant lesson positively influenced both the middle
school students and high school juniors in their understanding of engineering, their
confidence to succeed in engineering, and the importance of engineering for society.
In conclusion, the research overall exemplified the need for culture test systems to
be as sophisticated as the materials being investigated. In advancing understanding of
pathological conditions and simulation of physiological conditions, fundamental in vitro
evaluations of engineered bone devices can screen for potential incompetencies.
Characterization of bone constructs can target different pathological conditions to
examine specificity of bioactive molecules, cytokines, and nano-particles supplemented
on the devices. The long-term goal is to significantly improve characterization of
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technologies for pathological fractures by incorporating human mesenchymal and
hematopoietic stem cells from bone aspirates in normal and pathological co-culture and
tri-culture systems. Hence, results from this research will impact the advancement of
bone tissue engineering strategies by answering the increasing demands for efficiency in
engineered bone tissue and internal fixation devices. Awareness of the implications of
bone diseases can be disseminated to young students or future engineers with this unique
workshop that incorporates bone biology with fixation implant designs.
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CHAPTER SIX
RECOMMENDATIONS FOR FUTURE WORKS
1.

For clinical relevance, allografts can be obtained to co-culture cells and compare
with other commercially available bone constructs. It will be important to ensure
that all parameters are the same and all materials are sterilized according to
company standards.

2.

Once optimized, protective bone agents can be tested to understand coupling
inhibition or induction responses by both osteoclasts and osteoblasts for local
dosage determination and long-term systemic effects.

3.

For clinical relevancy, the cell ratio study and the tri-culture study should be
conducted using primary human cells. However, the test system should be
optimized for murine and human cells for labs that have no access to primary
cells.

4.

The tri-culture can be advanced into other models of pathological bone, modeling
with respect to the adipocytes, etc. Further characterization of the tri-culture will
be necessary to establish it as a osteoporotic model.

5.

For a more extensive understanding of osteoclastic and osteoblastic activity, a
longer differentiation/maturation period for tri-culture is recommended. In
addition, determine if adipogenic communication with bone cells affects activity
with tri-culture of differentiated osteoclasts and osteoblasts.

6.

Since tri-culture for bone cells are on a 3D bone matrix, adipocyte differentiation
should be conducted on a 3D hydrogel matrix to increase physiological relevance.
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However, attention should be paid to potential interactions of soluble factors
between bone cells and fat cells.
7.

Experiments should be conducted to determine different methods of measuring
osteoclastic activity. One approach would be to assess the protease activity of
cathepsin K or matrix metallopeptidase 9 (MMP-9) using zymography. Due to the
3D environment of the bone constructs, TRAP staining cannot be performed;
additionally, the use of ELF97 is general for all endogenous phosphatases. For
these reasons, ELISAs will need to be implemented to assess osteoclastic activity.
The TRAP ELISA was conducted, but it did not detect any of the samples
collected.

8.

An alternative to visually qualify osteoblasts and osteoclasts on the substitute
materials is to trypsinize or isolated the mature/active cells from the material to be
plated on tissue culture plastic well plates. Realize that this procedure will alter
cellular behavior, morphology, and population.

9.

To measure adipogenic activity, a triglyceride assay and gas chromatography
should be conducted to evaluate secreted fatty acid in the medium. Oil red O stain
can be conducted for adipocytes in 2D culture but, for 3D culture, a different
imaging method should be used.

10.

Depending on the bone construct, measurement of calcium phosphate and other
mineral deposition may not be possible with a chemical assay. One alternative is
to use energy-dispersion x-ray (EDX) via scanning electron microscopy (SEM).
Samples collected for Live/Dead imaging can be saved for SEM following sample
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fixation protocols.
11.

To improve upon the teaching model to make it more accessible for teachers and
instructors, plates should be revised using household items or items that are
commercially available.

12.

The styrofoam for the normal cancellous bone can be changed to something less
dense and stiff so that students can more easily insert screws. Also the
incorporation of a hollow styrofoam will eliminate the necessity to drill a hole
inside the tube.

13.

Survey questions should be altered to focus on just the bone implant lesson to
gain more insight on the effectiveness of the module in introducing biomedical
engineering and engineering design. However, the lesson itself then needs to be
expanded upon to be more than an hour to complement the entirety of the survey.

14.

A follow up student event should be developed to reinforce the initial information
and to study the long term effects of a long lesson versus a short 1-hour education
module.
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Appendix A
Mono-culture Results
Comparison of differentiation in mono-culture; D1 and RAW cells differentiating into
osteoblasts and osteoclasts, respectively, on 2D well plate and 3D chronOS granules at
Day 14. Samples were collected at Days 4, 8 and 14.

a)

b)
Figure A1. Fluorescent images
of mono-culture of D1 cells under (a)
negative control (only growth medium),
(b) 2D osteoblastic differentiation with
osteogenic medium, and (c) 3D
osteoblastic differentiation with
osteogenic conditions. Cells were
probed with Hoechst nuclear stain
(blue), AlexaFluor 546 actin stain (red),
and ELF97 endogenous phosphatase
stain (green).

c)

114
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Gene	
  Expression	
  and	
  Significance	
  
Marker	
  

Time	
  

Matrix	
  

Time*Matrix	
  

ALP	
  

0.0025	
  

-‐	
  

-‐	
  

Runx2	
  

0.0160	
  

-‐	
  

-‐	
  

OCN	
  

0.0025	
  

0.0102	
  

0.0180	
  

CapK	
  

<0.0001	
  

-‐	
  

0.0403	
  

RANK	
  

0.0121	
  

0.0087	
  

0.0144	
  

Significance	
  of	
  effects	
  and	
  interaction	
  of	
  effects	
  is	
  shown	
  for	
  each	
  marker.	
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Appendix B
Bone Implant Teaching Module
The presentation is accessible through DropBox:
https://www.dropbox.com/s/uwk7qfpzzed5khb/Biomedical%20Engineering%20Worksho
p.pptx
To modify presentation, enter password: BME
The presentation includes instructions, notes, and suggestions for teachers to modify to
meet the standards for grade level, class subject, and class size.

116

117

118

119

Survey Questions given to the Girl Scouts in middle school and Juniors in high school:
Please	
  check	
  one	
  box	
  for	
  each	
  statement.	
  
Strongly	
  
	
  
Disagree	
  
Disagree	
  
I	
  like	
  math	
  
	
  
	
  
I	
  like	
  science	
  
	
  
	
  
I	
  like	
  engineering	
  
	
  
	
  
It	
  is	
  important	
  for	
  me	
  to	
  
	
  
	
  
learn	
  math	
  
It	
  is	
  important	
  for	
  me	
  to	
  
	
  
	
  
learn	
  science	
  
It	
  is	
  important	
  for	
  me	
  to	
  
	
  
	
  
learn	
  engineering	
  
I	
  am	
  good	
  at	
  math	
  
	
  
	
  
I	
  am	
  good	
  at	
  science	
  
	
  
	
  
I	
  am	
  good	
  at	
  engineering	
   	
  
	
  
I	
  can	
  be	
  a	
  mathematician	
   	
  
	
  
I	
  can	
  be	
  a	
  scientist	
  
	
  
	
  
I	
  can	
  be	
  an	
  engineer	
  
	
  
	
  
Mathematicians	
  help	
  
	
  
	
  
people	
  
Scientists	
  help	
  people	
  
	
  
	
  
Engineers	
  help	
  people	
  
	
  
	
  

No	
  
Opinion	
  

Strongly	
  
Agree	
  

Agree	
  

	
  
	
  
	
  

	
  
	
  
	
  

	
  
	
  
	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  
	
  
	
  
	
  
	
  
	
  

	
  
	
  
	
  
	
  
	
  
	
  

	
  
	
  
	
  
	
  
	
  
	
  

	
  

	
  

	
  

	
  
	
  

	
  
	
  

	
  
	
  

Open-‐ended	
  questions:	
  
What	
  do	
  mathematicians	
  do?	
  
What	
  do	
  scientists	
  do?	
  	
  
What	
  do	
  engineers	
  do?	
  
How	
  do	
  mathematicians	
  help	
  people?	
  
How	
  do	
  scientists	
  help	
  people?	
  
How	
  do	
  engineers	
  help	
  people?	
  
	
  
Additional	
  questions	
  given	
  on	
  post-‐survey	
  (with	
  rating	
  scale)
I	
  learned	
  what	
  electrical	
  engineers	
  do	
  
I	
  will	
  tell	
  my	
  friends	
  and	
  family	
  about	
  what	
  I	
  learned	
  in	
  electrical	
  engineering	
  class	
  
I	
  learned	
  what	
  mechanical	
  engineers	
  do	
  
I	
  will	
  tell	
  my	
  friends	
  and	
  family	
  about	
  what	
  I	
  learned	
  in	
  mechanical	
  engineering	
  class	
  
I	
  learned	
  what	
  bioengineers	
  do	
  
I	
  will	
  tell	
  my	
  friends	
  and	
  family	
  about	
  what	
  I	
  learned	
  in	
  bioengineering	
  class	
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